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Plant products have been used for a long time in treatment of diseases. In fact, 
more than half of approved medicines are derived from plants or other natural products. 
Even though the synthetic drugs are effective in treating many human diseases, there is 
no cure against several clinical disorders.  Moreover, a significant number of diseases can 
be prevented thereby causing less burden on societal healthcare costs as well as 
promoting healthy lifestyles.  Thus, botanicals offer a unique opportunity to explore 
novel compounds to prevent and treat various clinical disorders as well as understand 
their mode of action so that new targeted therapeutics can also be developed.   
For that reason, we studied the efficacy of two different natural products in 
treatment of two diseases models and explored the mechanism behind their therapeutic 
effects in both diseases. The first one was asthma mouse model treated with resveratrol. 
Asthma is a chronic inflammatory disease of airways mediated by T-helper lymphocytes 
(Th2) cells involving complex signaling pathways.  Resveratrol, a phytoallexin, has been 
previously shown to attenuate allergic asthma although the role of miRNA in this process 
has not been studied. In the current study, we investigated the effect of resveratrol on 
ovalbumin-induced experimental allergic asthma in mice.  To that end, BALB/c mice 
were immunized with ovalbumin (Ova) intraperitoneally followed by oral gavage of 
vehicle (Ova-veh) or resveratrol (100 mg/kg body) (Ova-res).  On day 7, the 
experimental groups received intranasal challenge of Ova followed by 7 days of 
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additional oral gavage of vehicle or resveratrol. At day 15, all mice were euthanized and 
bronchioalveolar fluid (BALF), serum and lung infiltrating cells were collected and 
analyzed.  The data showed that resveratrol significantly reduced IL-5, IL-13, and TGF-β 
in the serum and BALF in mice with Ova-induced asthma.  Also, we saw a decrease in 
CD3+CD4+, CD3+CD8+, and CD4+IL-4+ cells in pulmonary inflammatory cell 
infiltrate in Ova-res group when compared to Ova-veh.  MiRNA expression arrays using 
lung infiltrating cells showed that resveratrol caused significant alterations in miRNA 
expression, specifically downregulating the expression of miR-34a.  Additionally, miR-
34a was found to target FOXP3, as evidenced by enhanced expression of FOXP3 in the 
lung tissue.  Also, transfection studies showed that miR-34a inhibitor upregulated FOXP3 
expression while miR-34a-mimic downregulated FOXP3 expression.  The current study 
suggests that resveratrol attenuates allergic asthma by downregulating miR-34a that 
induces increased expression of FOXP3, a master regulator of T-regulatory cells (Treg) 
development and functions. 
The pivotal roles of the microbiota residing along mucosal surfaces, both local 
and distal to the afflicted site, have garnered an appreciation in the field of immunology 
when studying autoimmune disorders. In this study we focused on the bioactive molecule 
resveratrol (RES), a polyphenol compound derived from plants. Resveratrol is known for 
its multifaceted approach to combat autoimmune disorders via its anti-inflammatory, 
anti-microbial and anti-oxidative properties. In this study, we focused on the direct 
effects of resveratrol supplementation on the clinical symptoms of ovalbumin (OVA)-
induced murine allergic response, as well as the effects on bacterial composition of the 
pulmonary tract and the cecum, and on the expression of tight junction-regulating genes 
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in the lung epithelium. We found that resveratrol induced colonization of Akkermansia 
muciniphila in the lung tissue and Bacteroides acidifaciens in the colon of resveratrol-
treated OVA-stimulated mice, relative to VEH-treated mice. In addition, we found that 
RES induced significant changes in tight junction and PPAR-γ gene expression in 
pulmonary epithelium of OVA-stimulated mice treated with RES, when compared to 
those mice treated with VEH. We conclude that RES has promising efficacy in the 
treatment of asthma and its effect may be mediated by changes in gut-lung microbiome 
axis.   
The second disease model we studied was neuroblastoma; Neuroblastoma (NBL) 
is one of the most common childhood cancers that originate from the immature nerve 
cells of the sympathetic system. Studies with NBL cancers have also shown that miRNAs 
are dysregulated and may play a critical role in pathogenesis. Cannabidiol (CBD) is a 
non-psychoactive compound found in marijuana which has been previously shown by our 
laboratory and others to induce apoptosis in cancer cells.  However, there are no studies 
reported to test if CBD mediates these effects through regulation of miRNA.  In the 
current study, therefore, we investigated if CBD induces apoptosis in human NBL cell 
lines, SH SY5Y and IMR-32, and if it is regulated by miRNA. Our data demonstrated 
that CBD induces apoptosis in NBL cells through activation of serotonin and vanilloid 
receptors.  We also found that caspase-2 and -3 played an important role in the induction 
of apoptosis. CBD also significantly reduced NBL cell migration and invasion in vitro. 
Furthermore, CBD blocked mitochondrial respiration and caused a shift in metabolism 
towards glycolysis. CBD altered the expression of miRNA specifically, down-regulating 
hsa-let-7a and upregulating hsa-mir-1972. Downregulation of let-7a increased expression 
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of target caspase-3, and growth arrest specific-7 (GAS-7) genes. Upregulation of hsa-mir-
1972 caused decreased expression of BCL2L1 and BCL2 genes. Together, our studies 
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Inflammation can be defined as a defense response of a living object to different 
injurious stimuli whether endogenous or exogenous [1]. Generally, inflammation can be 
divided according to: duration, etiology, consequences, severity and mechanism [2]. The 
host response to inflammation is well-organized, highly regulated and well-controlled by 
elaboration of numerous immune and non-immune cells, cytokines, chemokines, and 
various lipid mediators [3]. The change in human environment including food habits, 
physical activity, hygiene and population growth has promoted increase in susceptibility 
to develop inflammation [4]. Inflammatory response can be classified into two phases; 
acute phase (that continues up to 2 weeks) and chronic phase (that continues more than 2 
weeks) [5]. The acute phase is strictly controlled by pro-inflammatory mediators and is 
characterized by vasodilation, extravasation of fluid and recruitment of neutrophils [6]. 
After neutralization of inflammatory stimuli, the recruited neutrophils will undergo 
apoptosis and the macrophage will take the responsibility of cleaning the affected area 
and restoration of normal tissue architecture [7].  The orchestrated activation of different 
signaling pathways in inflammation involves various mediators; the widely studied 
cytokines are regarded the main players [8]. Cytokines are small sized proteins with a 
molecular weight between 8-40,000d secreted from the cells at different conditions [9]. 
The proinflammatory cytokines that play a pivotal role in inflammation induction are 
numerus, among them IL-1 and TNF are well studied [10]. The family of cytokines also 
includes a family of receptors named Toll-Like Receptors (TLRs) which have the ability 
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to distinguish the microbial pattern [11]. TLRs are genetically preserved molecules 
capable of distinguishing exogenous micro-organisms and non-self-recognition [12]. 
Although these receptors are structurally different, their downstream signaling remains 
similar; the control of survival in case of DD (death domain) or adaptor protein 
recruitment in case of T1R [13]. Upon recruitment of adaptive proteins, different protein 
kinases are activated like IRAK in case of activating T1R or RIP in case of TNFR family 
activation [14, 15]. The function of these receptors is to recognize and getting activated 
by the microbial antigens whether surface antigens, nuclear acids, lipoproteins and 
damage-associated molecular patterns both in direct and indirect way [16]. 
Vascular changes occurs during acute phase are driven mainly by histamine, 
prostaglandins and nitric oxide which are responsible for inducing vascular smooth 
muscle relaxation, vasodilation, and accumulation of recruited leukocytes at the site of 
inflammation [12]. At the same time, histamine and leukotrienes act on vascular 
endothelial cells to increase vascular permeability followed by extravasation of 
inflammatory exudate and inflammatory cells to the extracellular space [13]. On the other 
hand, IL-1 and TNF play an important role in increasing the expression of endothelial 
cell adhesion molecules (ICAM and VCAM) to promote leukocytes extravasation to the 
extracellular space [14]. 
The pro-inflammatory signaling pathway has the ability to induce anti-
inflammatory response at the same time [8]. Recently, several researchers have shown 
that activation of TLR in acute inflammatory reaction can simultaneously trigger anti-
inflammatory response via increasing expression of IL-10 along with the pro-
inflammatory response [15]. At the level of adapter protein, there will be either activation 
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through TRAF-3 or TRAF6 which induce IL-10 and IL-6 or IL-12 respectively [15]. The 
balance between these two-pathways mediated by TRF-3 and TRF-6 results in failure of 
inflammation resolution and progression to chronic inflammation [13]. The strict control 
of inflammatory response is mandatory to regain the cellular phenotype and resolve the 
tissue insult [16]. The first event in resolution of inflammation is the clearance of 
infiltrating cells represented by polymorph nuclear cells and absorption of extracellular 
fluid [17]. Recently, several researchers have named the molecular mediator of resolution 
[18-20].  The most important mediators in the process of inflammation resolution are the 
lipid mediators [17]. The lipid mediators can be pro-inflammatory such as eicosanoids, 
anti-inflammatory such as resolvins, protectins or have dual action such as lipoxin4 [21, 
22]. It has been shown before that COX-2 derived prostaglandins exerts a potent anti-
inflammatory action specifically PGI2 and 15d-PG-J2 [23]. These two mediators are 
responsible for clearance of infiltrating neutrophils by the process of apoptosis [24]. In 
addition, there is increased evidence that these prostaglandins play an important role in 
resolving signaling in addition to neutrophil apoptosis [25].  The apoptotic cell remnants 
are cleared by the process of phagocytosis accomplished by scavenger macrophages 
(extravasated blood-monocytes) [26]. Impairment of apoptosis or defects in phagocytosis 
leads to progression of acute inflammation to chronic inflammation [27, 28].  
Chronic inflammation unlike the acute one, continues for more than 2 weeks and 
up to several years and is followed by permanent tissue damage [29]. The main reason of 
chronic inflammation is failure of strictly control process of resolution following acute 
inflammatory reaction [30]. Allergic inflammation is a distinct type of inflammation 
against non-infectious antigens called allergens  such as pollens, dendrite, hay, animal 
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product, dust and others [31]. Acute allergic inflammation has two phases; the acute 
phase (initial phase) occurs within minutes of exposure to allergens and the late phase 
that occurs after 2-6 hours of allergen exposure and continues for 1-2 days and it can be 
local or systemic clinical manifestation [31]. Asthma is a chronic allergic inflammation 
characterized by acute attacks of cough, bronchospasm and excessive mucous production 
[32]. Currently there is no cure from asthma and different approaches have been 
attempted to reduce the inflammatory reaction with steroids and improve 
bronchoconstriction with bronchodilators [33, 34]. The role of microbiome residing in the 
gut and the lung in human well-being has been recently well-developed via improvent of 
genotyping methods away from culture [35]. There is a convincing body of evidence 
suggests the link between the lung microbiome and development of asthma and chronic 
obstructive airway diseases [36, 37]. Recently, the role of environmental factors and 
gastrointestinal microbiome got great attention because many epidemiological studies 
showed the difference in asthma incidence in different environmental conditions [38, 39].  
Due to the fact that asthma is mostly seen in pediatric age group and the present treatment 
strategy has several side effects, the need for natural anti-inflammatory treatment free of 
adverse reactions rises [40]. 
One of the most dangerous complications of chronic inflammation is the 
development of cancer [41, 42]. There is growing evidence indicating that inflammation 
plays a vital role in development of many cancers including mesothelioma, lung 
carcinoma, bladder cancer, colorectal cancer and esophageal carcinoma [42-45]. 
Infiltrating chronic inflammatory cells release reactive oxygen and nitrogen species 
which in turn induce permanent DNA damage in the proliferating cells [46]. Furthermore, 
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the released reactive species also react at the site of infection and produce carcinogenic 
material known as peroxynitrite [46]. Cycloxygenase (COX2) is a pro-inflammatory 
mediator that has been shown to be overexpressed in neuroblastoma and non-steroidal 
anti-inflammatory drugs were effective in inducing tumor apoptosis [47-50]. As 
Cannabidiol (CBD) is a well-known anti-inflammatory drug and is free of psychoactive 
side effect, we considered testing the effect of CBD on neuroblastoma cells. 
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CHAPTER 1
RESVERATROL ATTENUATES ALLERGIC ASTHMA AND 
ASSOCIATED INFLAMMATION IN THE LUNGS THROUGH 
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Asthma is a chronic inflammatory disease of airways mediated by Th2 cells 
involving complex signaling pathways. Although resveratrol has previously been shown 
to attenuate allergic asthma, the role of miRNA in this process has not been studied. we 
investigated the effect of resveratrol on ovalbumin-induced experimental allergic asthma 
in mice. To that end, BALB/c mice were immunized with ovalbumin (OVA) 
intraperitoneally followed by oral gavage of vehicle (OVA-veh) or resveratrol (100 
mg/kg body) (OVA-res). On day 7, the experimental groups received intranasal challenge 
of OVA followed by 7 days of additional oral gavage of vehicle or resveratrol. At day 15, 
all mice were euthanized and bronchioalveolar fluid (BALF), serum and lung infiltrating 
cells were collected and analyzed. The data showed that resveratrol significantly reduced 
IL-5, IL-13, and TGF-β in the serum and BALF in mice with OVA-induced asthma. 
Also, we saw a decrease in CD3+CD4+, CD3+CD8+, and CD4+IL-4+ cells in 
pulmonary inflammatory cell infiltrate in OVA-res group when compared to OVA-veh. 
miRNA expression arrays using lung infiltrating cells showed that resveratrol caused 
significant alterations in miRNA expression, specifically downregulating the expression 
of miR-34a. Additionally, miR-34a was found to target FOXP3, as evidenced by 
enhanced expression of FOXP3 in the lung tissue. Also, transfection studies showed that 
miR-34a inhibitor upregulated FOXP3 expression while miR-34a-mimic downregulated 
FOXP3 expression. The current study suggests that resveratrol attenuates allergic asthma 
by downregulating miR-34a that induces increased expression of FOXP3, a master 
regulator of Treg development and functions.  
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1.2. Introduction 
Asthma is a chronic inflammatory condition driven by Th2- immune response 
characterized by cough, shortness of breath and impairment of lung function which might 
be life threatening [1]. The inflammation in asthma leads to increase airway hyper-
responsiveness and bronchial spasm and excessive mucous production [2]. There are 
several cellular signaling pathways that are disrupted in asthma resulting in continuous 
inflammatory response often to harmless substances such as dendrites and pollen [3]. One 
of the disrupted pathways, most often found, comprises of changing the expression of co-
stimulatory molecules and cytokines secretion [4]. As a Th2-driven inflammatory 
response, asthma is characterized by increase in the levels of IL-4, IL-5, IL-13 and GM-
CSF along with an increase in the level of TNF-α and TGF-β in BALF and serum,  which 
primarily act as pro-inflammatory cytokines [5]. It is well known that asthma and 
autoimmune diseases with impaired peripheral tolerance are associated with T-regulatory 
cell dysfunction [6]. T-regulatory (T-regs) cells are subpopulation of T-cells responsible 
for dampening the immune response, maintenance of peripheral tolerance and prevention 
of chronic inflammation [7]. T-regs are known to express CD4 and CD25 surface 
molecules in addition to secretion of anti-inflammatory cytokines represented by IL-10 
[8]. The most important transcription factor for T-reg is FOXP3, which plays an 
important role in their differentiation and development [9]. In fact, the knockdown of 
FOXP3 results in development of autoimmune diseases in multiple organs due to absence 
of properly functioning T-regs [10]. Tregs have been found to be defective in both 
number and function in allergic disease and their mutation has been linked to exaggerated 
immune response [11-15]. 
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micro-RNAs (miRNAs) are small, ~22 nucleotide long, non-coding, regulatory 
RNAs that play a critical role in the regulation of gene expression at the post-
transcriptional level. miRNAs play a significant role in driving asthma-related immune 
responses, although the exact role and subsequent downstream pathways of regulation 
remain obscure. Significant alterations in the expression of miRNA in 
airway epithelial cell have been reported in asthma [16]. These alterations are only 
modestly corrected by inhaled corticosteroids [16], thereby showing that alternative 
modes of treatment are critical that could alter miRNA expression. 
Resveratrol is a poly-phenolic stilbene (3, 4, 5-trihydroxystilbene) which is 
abundant in wine, skin of red grapes, berries, and peanuts [10, 17, 18]. Several previous 
studies demonstrated that resveratrol has anti-carcinogenic, anti-inflammatory and 
cardio-protective effects [10, 19, 20]. Asthma is one of the diseases in which T-regs 
function is impaired, and the response of asthmatic patient to systemic or inhaled steroid 
is attributed mainly to their ability to induce immunosuppression via T-reg cell activation 
[6]. The non-availability of a specific drug to target the downstream pathways of Th2-
driven mechanisms and their modulations by miRNAs restricts therapy in these 
conditions [21]. The situation is also complicated by an overdependence on long acting 
corticosteroids, which has potential side effects [22-24]. We and others have shown that 
resveratrol is highly effective in suppressing inflammation in many autoimmune disease 
models [25-27] Furthermore, researchers have shown that resveratrol is as effective as 
steroids in treatment of asthma [28, 29]. However, the role of miRNA in resveratrol-
mediated attenuation of allergic asthma, its ability to induce the expression of FOXP3, a 
master regulator of Tregs and immunosuppression, has not been previously investigated. 
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In the current study, we used a murine model of asthma to study the therapeutic effects of 
resveratrol and to address the role of miRNA. Our results showed that resveratrol induces 
the repression of miR34a leading to over expression of FOXP3 as a possible mechanism 
of attenuation of allergy/asthma symptoms in mice. 
1.3. Materials and methods 
1.3.1. Animals 
Female BALB/c mice aged 6-8 weeks were purchased from Jackson laboratories. 
All mice were housed in specific pathogen-free conditions at the AAALAC-accredited 
animal facility at the University of South Carolina, School of Medicine (Columbia, SC). 
All experimental procedures performed were approved by the University of South 
Carolina Institutional Care and Use Committee (IACUC). They were maintained under a 
12 h light/dark cycle at an ambient temperature of 24 ± 1°C in a specific pathogen-free 
animal facility. They received ad libitum access to normal chow diet and water. Cages 
were cleaned every other day and enrichment items were renewed at the same time. The 
mice were kept in the facility for at least a week for acclimatization before use for the 
experiments.  
1.3.2. The effect of resveratrol on asthmatic lungs  
Previous studies have shown that female BALB/c mice develop asthma easily 
[30-32]. Therefore, female BALB/c mice were used to develop asthma in this study. The 
mice were divided randomly into three groups (Naïve, OVA-vehicle; OVA-veh, and 
OVA-resveratrol; OVA-res) in isolated cages. The mice of Naïve group did not get any 
treatment whereas, the mice of the other two treatment groups were first sensitized 
intraperitoneally with 250µg of chicken egg-derived ovalbumin (OVA), dissolved in a 
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solution of aluminum hydroxide (4 mg/ml) in a sterile phosphate buffer saline without 
Ca++ and Mg++ (PBS), and this day was designated as day 0 of the study [33]. On day 7, 
both sensitized groups of mice were challenged with 50µg OVA suspended in 50 µl of 
sterile PBS intranasally under light anesthesia on day 7. The mice of treatment group 
(OVA-res) were administered 100 mg/kg resveratrol dissolved in carboxyl methyl 
cellulose (CMC) in volume of 200µl daily from day 1 through day 14 of the experiment 
by oral gavage [17, 34-36] . We chose the dose (100 mg/kg bw) of resveratrol based on 
our previous studies gavage [17, 34-36].  The mice of vehicle treatment group (OVA-
veh) were given CMC (200 µl) by oral gavage. All the mice were euthanized on day 15 
under anesthesia. Previous studies have shown that female BALB/c mice develop asthma 
easily [30-32]. Therefore, female BALB/c mice were used to develop asthma in this 
study. The mice were divided randomly into three groups (Naïve, OVA-vehicle; OVA-
veh, and OVA-resveratrol; OVA-res) in isolated cages. The mice of Naïve group did not 
get any treatment whereas, the mice of the other two treatment groups were first 
sensitized intraperitoneally with 250µg of chicken egg-derived ovalbumin (OVA), 
dissolved in a solution of aluminum hydroxide (4 mg/ml) in a sterile phosphate buffer 
saline without Ca++ and Mg++ (PBS), and this day was designated as day 0 of the study 
[33]. On day 7, both sensitized groups of mice were challenged with 50µg OVA 
suspended in 50 µl of sterile PBS intranasally under light anesthesia on day 7. The mice 
of treatment group (OVA-res) were administered 100 mg/kg resveratrol dissolved in 
carboxyl methyl cellulose (CMC) in volume of 200µl daily from day 1 through day 14 of 
the experiment by oral gavage [17, 34-36]. We chose the dose (100 mg/kg bw) of 
resveratrol based on our previous studies gavage [17, 34-36].  The mice of vehicle 
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treatment group (OVA-veh) were given CMC (200 µl) by oral gavage. All the mice were 
euthanized on day 15 under anesthesia.  
1.3.3. Histopathology of the lung 
After euthanasia, the lungs were harvested and then perfused with 4% 
paraformaldehyde in 0.1 M PBS. After perfusion, harvested lung tissues were first fixed 
in formalin solution (10%) and then were embedded in paraffin blocks. Paraffin sections 
of lung tissue were cut using a microtome to a thickness of (5 µm). The lung sections on 
slides were stained with Hematoxylin and Eosin (H&E) dyes. H&E stained lung tissue 
sections were assessed for histological changes and the cellular infiltration into the lung 
tissues were analyzed using Leica DM 2500 fluorescent microscope (Buffalo Grove, IL, 
USA).  
1.3.4. Analysis of Cytokines 
The generation of cytokines post vehicle or resveratrol treatment was analyzed in 
the bronchoalveolar lavage fluid (BALF) and blood sera. The analysis of cytokines in 
BALF was performed using the protocol as described previously [37] . Briefly, trachea 
was first tightened using suture and then lungs were isolated as an intact organ with 
sutured trachea. Then, sterile ice-cold PBS (1ml) was injected into the trachea and the 
draining fluid (BALF) was collected. The collected BALF was centrifuged at 300xg for 
15 minutes and the supernatant was collected and used for cytokines analysis. To analyze 
cytokines in sera, blood was on day 15 from the retro-orbital space under light anesthesia. 
The serum was isolated by centrifugation at 300xg for 15 minutes at 4°C. The collected 
supernatant was used for cytokine analysis by ELISA. 
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 Cytokines in collected BALF and sera were detected using sandwich enzyme-
linked immunosorbent assay (ELISA) kits for IL-5 and IL-13, obtained from Affymetrix 
(Santa Carla, CA, USA) and free-TGF-β ELISA kit, obtained from Biolegend (San 
Diego, CA, USA). The protocols of the companies were followed to perform ELISA. The 
absorbance values were measured by Vector2 microplate reader from PerkinElmer 
(Boston, MA). 
1.3.5. Analysis of lung infiltrating by Flow cytometry. 
Lung infiltrating cells were analyzed by flow cytometry. Lung infiltrating cells 
were isolated using Histopaque and following the protocol as described earlier [38]. In 
brief, lungs were first perfused with cold PBS and then harvested from various treatment 
groups and ingle cell suspensions were prepared as described earlier [39, 40]. RBC lysis 
buffer from Biolegend (San Diego, USA) was added (250 µl/lung) for 1 minute to lyze 
the red blood cells. FACS buffer was then added and the cells were collected by 
centrifuging at 300xg for 10 minutes at 4ºC. Next, the cells were suspended in 5 ml of 
FACS buffer and then Histopaque (at room temperature) was added. The Histopaque 
columns containing cells were centrifuged at 500xg for 30 minutes at room temperature. 
The cells present in the interphase layer were carefully collected to another 15 ml tube 
containing 10 ml of PBS. The cells were collected and then washed twice in complete 
medium (Dulbecco`s Modified Eagle Medium (DMEM) supplemented with 10% FBS, 
1% pencillin/streptomycin). The collected cells were suspended in complete medium and 
the cells were counted using automated cell counter from Bio Rad (Hercules, CA, USA). 
The cells were then stained using fluorophore labeled surface markers. Staining with 
antibodies against intracellular cytokine was performed using Fixation/Permeabilization 
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Solution Kit (BD, San Jose, CA, USA). Probing the intranuclear transcription factors was 
done using True-nuclear Transcription Factor Buffer ser (Biolegend, San Diego, CA, 
USA). The following antibodies; PE-Anti-mouse anti-CD3 conjugated with PE or 
PE/cy5.5 florochrome,, anti-mouse anti-CD4 conjugated with PE/cy7, FITC or 
APCflorophore, , Anti-mouse anti-CD8 conjugated with FITC, anti-mouse anti-IL-4 
conjugated with PE/cy7 florophore, Antimouse antiCD25 conjugated BV-786, and anti-
mouse anti-FOXP3 conjugated with PE. were used for staining the cells. The stained cells 
were then analyzed using BD-FACSCelesta flow cytometer and their DIVA software 
(BD Biosciences, San Diego, CA). CD3CD4 and CD3CD8 was expressed as total cell 
number in the analysis by multiplying the percentage of expression by the cell count for 
that mouse. 
1.3.6. miRNA array 
For miRNAs arrays, total RNAs including miRNAs isolated from lung infiltrating 
cells were used. In brief, total RNAs from lung infiltrating cells were isolated using RNA 
assay kit from Qiagen (Valencia, MD, USA) and following the protocol of the company. 
Total RNAs were then labeled using kit from Qiagen and following the protocol of the 
company labeling.  Briefly, volume and concentration of RNAs from various samples 
were adjusted and then control oligonucleotides were added. Ligase was added to ligate 
the RNAs end to biotin. The labeled miRNAs from various samples were added to the 
cartridges and hybridization was performed. After 18 hours of hybridization, the 
cartridges were washed and stained using GCS3000 System from Affymetrix (Santa 
Carla, CA, USA) and following the manufacturer’s protocols. The cartridges were then 
scanned using Affymetrix scanner. The results were analyzed using Expression Console 
15 
software from Affymetrix. The dysregulated miRNAs were then analyzed using 
Ingenuity Pathway Analysis (IPA) software from Qiagen. 
1.3.8. Quantitative Real-Time PCR (qPCR) to validate miRNAs and genes 
expression.  
To validate the expression of miRNAs and genes of interest, total RNAs isolated 
from pulmonary infiltrating mononuclear cells from the lungs of Naïve, OVA-veh, and 
OVA-res groups were used. The concentration and the quality of RNAs were analyzed 
using Nanodrop 2000 (Thermo Fisher Scientific, Rockford, IL, USA). Equal amounts of 
RNAs were used for cDNA synthesis. To examine the expression of miRNAs, cDNAs 
were synthesized using miScript cDNA Synthesis kit and following the protocol of the 
company (Qiagen, Valencia, MD, USA). SYBR Green PCR kit from Qiagen was used 
and the protocol of the company was followed. To detect gene expression, SSO 
Advanced SYBR Green PCR kit (Bio-Rad, Hercules, CA) was used and the protocol of 
the company was followed. Real-Time PCR was performed for 39 cycles and the details 
are as follows: 30 sec 98ᴼC (denaturation step), 60 sec at 60ᴼC (annealing step) and 60 
sec at 72ᴼC (extension step, followed by incubation for 10 minutes at 72ᴼC. The gene 
expression was normalized to GAPDH. GAPDH housekeeping gene has been used 
because its expression is reliable for one kind of cells [41, 42]. The PCR results for 
results of miRNAs expression were normalized to Snord 96A (small nucleolar RNA, C/D 
box 96A is used as a control to assess the level of miRNA [43]. The details of miRNAs 
and primer sequences for genes used in qPCR are described in table.1.  
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1.3.9. Immunofluorescent and immunohistochemistry assay 
To assess FOXP3 protein expression, we performed immunofluorescent staining 
as described earlier [44]. The slides with sections of lung tissue were first deparaffinized 
according to the standard protocol, antigen retrieval was done using antigen-retrieval 
solution from Abcam (Cambridge, MA, USA). The slides were then washed with PBS 
twice, permeabilized with 0.01% Triton X-100 (Sigma) for 15 min, washed three times 
with PBS 5 min each, and then incubated overnight at 4ᴼC with primary antibody 
(mouse-specific FOXP3) antibody from Abcam (Cambridge, MA, USA) diluted in 1% 
FBS in PBS. Next, the slides were washed with PBS three times 10 minutes each and 
incubated with anti-mouse secondary antibody diluted in 1% FBS in PBS for 1 hour at 
37ᴼC followed by washing the slides three times with PBS. The slides were then stained 
with DAPI to show the nuclei of the cells and washed three times with PBS and finally 
mounted with Antifade Mounting Medium from Vector Labs (Burlingame, CA). The 
tissue was visualized and photographed using Leica Fluorescent microscope. 
For immunohistochemistry analysis, the lung tissues sections (5 µm thickness) 
were first deparaffinized using a standard protocol. Epitopes were retrieved using epitope 
retrieval solution and steamer (IHC-Word, Woodstock, MD). Endogenous peroxidases 
were blocked using 3% H2O2 for 10 minutes in dark followed by serum blocking. The 
tissue was incubated with primary antibody anti-FOXP3 (Abcam, Cambridge, MA, USA) 
at 4ºC overnight. Species-specific biotinylated secondary antibody and streptavidin 
conjugated with HRP (Abcam) were used to implement antigen-specific 
immunohistochemistry. The chromogenic substrate 3,3’-Diaminobenzidine (DAB) 
(Sigma Aldrich, St Louis, MD) was used followed by Mayer’s Hematoxylin solution 
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(Sigma Aldrich) as a counterstain. Sections were washed between the steps using 
phosphate buffered saline 1X. Finally, stained sections were mounted with Simpo-mount 
(GBI laboratories, Mukilteo, WA). Tissue sections were observed using Olympus BX51 
microscope (Olympus, America). Image Pro Plus software from Media Cybernetics 
(Rockville, MD) was used for morphometric analysis of images. 
1.3.10. Transfection of splenocytes with miR-34a. 
Splenocytes were collected from naïve female BALB/c mice were cultured in 
complete RPMI (Roswell Park Memorial Institute) medium supplemented with 10% 
Fetal Bovine Serum and 1% penicillin/streptomycin. The cells were seeded at density of 
2X10
5
 cells /well in 24-well plate and were activated with 1µg/ml SEB overnight [39]. 
The cells were then transfected either with 20 nmol mock control obtained from Qiagen 
or with miR-34a mimic or anti-miR-34a (inhibitor) using HiPerfect Transfection reagent 
from Qiagen. The transfected cells were cultured for 24-48 hours. The transfcted cells 
were then collected and used for total RNAs including miRNAs isolation. Total RNAs 
were then used for validation of miR-34a and FOXP3 gene expression. 
1.3.11. Statistical Analysis 
We used groups of five mice to study the role of resveratrol in OVA-induced 
allergy. One-way ANOVA with post-hoc Tukey`s test was used to compare between 
three groups. Student’s t-test was used to compare two groups. In all experiments, data 
were shown as mean ± S.E.M. and p <0.05 was regarded statistically significant.  
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1.4. Results 
1.4.1. Resveratrol treatment improves Th2-mediated immune response 
Asthma is an inflammatory condition mediated by T-helper-2 immune response, 
with increase in the level of IL-4, -5, and -13 [2]. To investigate the effect of resveratrol 
on asthmatic lungs, we studied three groups of mice: Naïve, OVA+vehicle (OVA-veh) 
and OVA+resveratrol (OVA-res).  Histopathology was performed by staining the lung 
sections with hematoxylin and eosin and the sections examined them under the Leica 
microscope (Buffalo Grove, IL, USA). The lung tissue of the OVA-veh group was 
congested due to presence of perivascular and perialveolar inflammatory cell infiltrate 
and fluid extravasation along with destruction of alveolar walls compared to naïve group. 
Treatment with resveratrol resulted in restoration of lung tissue architecture, reduction in 
the inflammatory cell infiltrate, and disappearance of inflammatory exudate. The 
parenchyma of the treated group (OVA-res) was comparable to the naïve group with 
normal alveolar wall, clearance of inflammatory cell infiltrate and reduced alveolar wall 
edema (Fig 1A).  
OVA-veh group showed a significant increase in the levels of IL-5, IL-13 and free 
active TGF-β in BALF when compared to the naïve group while these cytokines were 
significantly lower in BALF of OVA-res group when compared to OVA-veh (Fig 1B). 
Furthermore, the level of serum IL-13, and TGF-β but not IL-5 were significantly lower 
in the OVA-res group when compared to OVA-veh (Fig 1C). When we analyzed T cells 
in the lungs, we noted that the levels of CD3+CD4+ and CD3+CD8+ was significantly 
reduced in OVA-res group when compared to OVA-veh group (Fig 2). Also, 
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CD3+CD4+IL-4 (Th2 cells) were significantly lower in OVA-res group when compared 
to OVA-veh (Fig 2B). Furthermore, we looked for the expression of CD24+FOXP3+ 
(Tregs) cells, we found that there is significant increase in the percentage of Tregs cells in 
resveratrol treated group as compared to vehicle (Fig 2C).  
1.4.2. Treatment with resveratrol alters the miRNAs profile 
To investigate if the anti-inflammatory effects of resveratrol were mediated by 
miRNA, we isolated RNA from the three experimental groups and we used miRNA-
array 4.0 from Affymetrix Thermo Fisher Transcriptome Analysis Console to analyze 
the data. The heat map and volcano plot analysis showed that most of the altered 
miRNA were downregulated (Fig 3 A, B). Principal Component Analysis of two 
independent samples showed distinct clustering of miRNA profiles in naïve, OVA-
veh and OVA-res groups (Fig 3C).   
1.4.3. Resveratrol treatment leads to alterations in miRNAs that target FOXP3, 
IL-13, IL-10 and GATA-3.  
To identify the target genes, we uploaded those miRNAs demonstrating a fold 
change ≥2 or ≤-2 into IPA software (Qiagen) (Fig 4A). Next, we used the website, 
www.miRNA.org, to show the alignment between miRNA and target genes. Such an 
analysis led to identification of anti-inflammatory pathways such as FOXP3 
(transcription factor for T-regulatory cells) and IL-10 (Fig 4A) as potential targets of 
miRNA. In this analysis, we also identified that miR-34a may target FOXP3 gene (Fig 
4A), which was confirmed by gene alignment software (Fig 4B). Real-time qPCR 
analysis in lung infiltrating cells validated the findings that miR-34a was induced while 
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FOXP3 was suppressed in OVA-veh group and treatment with resveratrol led to 
significant downregulation miR-34a while increasing the levels of FOXP3 (Fig 4B). We 
also studied in these cells, genes related to Th2 such as GATA-3 (Th2-transcription 
factor) and IL-13 (Th2-related cytokine) and both were significantly downregulated in 
OVA-res when compared to OVA-veh (Fig 4B). Interestingly, IL-10 gene expression was 
also significantly higher in OVA-res when compared to OVA-veh (Fig 4C). 
1.4.4. Resveratrol treatment leads to induction of Foxp3+ cells in the lung 
To validate the PCR results of upregulated FOXP3 gene expression, we 
performed immunofluorescent staining of lung tissue slides. We calculated the corrected 
total cell fluorescence (CTCF) for FOXP3-stained cells in the lung tissue of naïve, OVA-
veh, and OVA-res group using ImageJ software from NIH. We found that CTCF for 
FOXP3 protein was significantly higher in OVA-res group when compared to naïve and 
OVA-veh group (Fig 5 A).  Moreover, immunohistochemistry staining of lung tissue 
section also showed significant increase in the levels of FOXP3 expression in OVA-res 
group when compared to OVA-veh (Fig 5B).  
To show further corroborate that the overexpression of FOXP3 was due to 
downregulation of miR-34a, we performed transfection studies using mock, miR-34a 
mimic or inhibitor in splenocytes that were activated with SEB. We observed that 
upregulation of miR-34a using a mimic, was associated with downregulation of FOXP3, 
while use of miR-34a inhibitor led to upregulation of FOXP3 gene (Fig 6). Together, 




Asthma is a common reason for morbidity in children and adults caused by 
chronic inflammatory response mediated by Th2-immune response [45-47]. Although a 
wide range of pharmacological therapies have been developed as a prophylactic treatment 
or to control acute asthmatic attacks such as β2-adrenergic drugs, steroids, IgE blockers, 
methylxanthines and leukotriene modifying agents, the most effective treatment stems 
from the use of steroids [48, 49]. However, steroids are associated with serious systemic 
side effects such as osteoporosis, cataract, growth retardation in children and 
immunosuppression [50]. Resveratrol, a polyphenolic stilbene is effective against asthma 
[50, 51] without the serious side effects as shown by many randomized clinical trials [52-
54]. In the current study we demonstrated that resveratrol can efficiently attenuate 
allergic asthma in a mouse model. These data are consistent with other studies 
demonstrating that resveratrol can suppress both airway inflammation and airway 
structural changes this gene, thereby potentially inhibiting the Th2-mediated immune 
response. in mouse models of bronchial allergic asthma [28, 51, 55, 56]. It is noteworthy 
that while such studies have identified many signaling pathways through which 
resveratrol can attenuate allergic asthma including suppression of expression of TGF-
β1/phosphorylated Smad2/3 [28], inhibition of  Syk protein expression [55], and 
increased expression of INPP4A in lungs which in turn reduced Akt kinase activity and 
Akt phosphorylation [51], the potential role played by miRNA in resveratrol-mediated 
attenuation of allergic asthma has not been previously investigated. In this study, we 
found that resveratrol treatment of ovalbumin-induced asthma in mice was associated 
with downregulation of several miRNA, particularly, miR-34a which targeted FOXP3 
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gene, a T-reg transcription factor, and caused significant induction of this gene, thereby 
potentially inhibiting the Th2-mediated immune response. 
The present study also showed that resveratrol treatment significantly reduced the 
levels of Th-2 cells and Th2-related cytokines (IL-5, and IL-13) in addition to asthma-
related cytokines such as TGF-β in BALF, and serum. The reduction in the level of 
asthma-related cytokines is an important indicator of suppression of inflammatory 
response [57, 58]. On the other hand, the level of IL-10 gene expression, encodes for an 
anti-inflammatory cytokine primarily secreted by T-regs, was also significantly higher in 
the pulmonary cell infiltrate from OVA-res group when compared to OVA-veh-treated 
group. This finding indicates that resveratrol may promote IL-10 mediated immune 
resolution as reported previously [59, 60]. These data on suppression of inflammation 
were consistent with our observation that the levels of CD3+CD4+, CD4+IL4+(Th2) and 
CD3+CD8+ was significantly reduced in Resveratrol treated group as compared to the 
asthma controls (OVA-veh).  
It has been shown previously that miRNA play an important role in regulation of 
inflammation. For example, in the innate immune system, miR-155 was shown to 
mediate the effect of LPS (lipopolysaccharide) on macrophages via TLR (Toll-Like 
Receptor) signaling pathway [61]. In addition, inflammatory response to infection in 
macrophages was mediated by upregulation of many miRNAs like miR-9, miR-21 and 
miR-149 [62-64]. The adaptive immune system was also proven to be regulated by 
miRNA alteration. Differentiation of naïve T-cell to effector T- cell was reported to be 
driven by miRNA regulation [65, 66]. In addition, miRNAs also regulate B-cell 
differentiation, maturation and activation [67-69]. Even though resveratrol can alter the 
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miRNA, very few studies mention the role of miRNA in resveratrol-mediated anti-
inflammatory effect in Ovalbumin-induced asthma [70-76]. In the current study, we 
found that miR-34a was significantly downregulated in OVA-res group as compared to 
OVA-veh. Moreover, we found that miR-34a showed good alignment with FOXP3 gene 
using IPA analysis and its subsequent downregulation by resveratrol treatment might 
significantly upregulate FOXP3. Following the same cues, we performed further studies 
to mimic or inhibit the expression of miR-34a by transfecting the cell with Hi-perfect 
miR-34a mimic or inhibitor and compared that with mock control. The results showed 
that the over-expression of miR-34a significantly downregulated FOXP3 gene and the 
administration of the mir-34a inhibitor significantly upregulated FOXP3 gene when 
compared to mock control. Taken together, these findings indicated that anti-
inflammatory effect of resveratrol in ovalbumin induced asthma may be mediated by 
downregulation of miR-34a which in turn upregulated FOXP3.  
It has been shown previously that miRNA play a central role in the induction of 
Tregs [77]. For example, deletion of miRNAs by lineage-specific ablation of Dicer or 
Drosha in T cells was found to decrease the number of Tregs, leading to fatal multi-organ 
inflammatory disease [78]. Also, miR-155 knock out (KO) mice have reduced numbers 
of FOXP3+ cells [79]. Since such reports, many studies have identified other miRs such 
as miR-10b, miR-99a, miR-130a, miR-146b, miR-150, and miR-320 that can drive Treg 
differentiation [77]. While the role of miR-34a in regulating FOXP3 expression and Treg 
induction has not been previously reported, we found one study in which 
lipopolysaccharide suppressed miR-34a leading to upregulation of CCL2, a macrophage-
derived chemokine that recruits Tregs [80].  
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In the current study, we also noted that OVA-sensitized mice showed higher 
levels of TGF-β and resveratrol treatment led to decrease in this cytokine production. 
Interestingly, TGF-β plays many roles. In asthma, TGF-β acts as a major mediator 
involved in pro-inflammatory responses and fibrotic tissue remodeling within the 
asthmatic lung [81]. It is also known to promote Th2 cytokine profile and elevated TGF-β 
levels have been detected in asthmatic airway [81]. These observations are consistent 
with our current study in which we found that TGF-β levels were upregulated in OVA-
exposed mice and that treatment with resveratrol led to significant decrease in TGF-β 
levels. Thus, resveratrol may also help suppress lung inflammation by targeting TGF-β. 
TGF-β is also known for its Yin-Yang role and thus, it can also induce Tregs [82]. 
However, in our model, it is more likely that the Treg induction by resveratrol may stem 
from its action on miR-34a.   
The limitation of this study was using female BALB/C mice, which was due to 
the fact that they are more susceptible to get allergic airway diseases than males. In 
addition, we need to validate the results by doing in-vivo tranfection with miR-34a mimic 
and inhibitor and look at the ability of them to develop allergic airway diseases. 
 In summary, our study showed that oral administration of resveratrol suppressed 
the asthma-associated immune response and its action was mediated by upregulation of 
FOXP3 induced by miR-34a down-regulation. To the best of our knowledge, we report a 
novel finding that resveratrol improves asthma via its effect on FOXP3 expression in 
pulmonary infiltrating cell and its therapeutic effect is mediated by miR-34a inhibition. 
This study will go a long way in establishing therapeutic strategies in treatment of asthma 
without the anti-asthmatics-associated side effects.  
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Table 1.1 Primer sequences for qPCR analysis of lung infiltrating cells and associated 
miRNA. 
 
FOXP3 (Forward) 5`-CCCATCCCCAGGAGTCTTG-3` 
FOXP3 (Reverse) 5`-ACCATGACTAGGGGCACTGTA-3` 
IL-13 (Forward) 5`-CCTGGCTCTTGCTTGCCTT-3` 
IL-13  (Reverse) 5`-GGTCTTGTGTGATGTTGCTCA-3` 
IL-10 (Forward) 5`-GCTCTTACTGACTGGCATGAG-3` 
IL-10 (Reverse) 5`-CGCAGCTCTAGGAGCATGTG-3` 
GATA3 (Forward) 5`-CTCGGCCATTCGTACATGGAA-3` 
GATA3 (Reverse) 5`-GGATACCTCTGCACCGTAGC-3` 
GAPDH (Forward) 5`-AGGTCGGTGTGAACGGATTTG-3` 





Figure 1.1 Resveratrol attenuates Ova-induced asthma: As detailed in Methods, mice 
were administered Ovalbumin (OVA) intraperitoneally followed by intranasal challenge 
and treated with vehicle (OVA-veh) or 100mg/kg Resveratrol (OVA-res) daily by oral 
gavage for 2 weeks and sacrificed on day 15.  (A) Histopathological analysis of the lungs. 
Significant thickening was observed in the alveolar walls and inflammatory cell 
infiltration as well as accumulation of edematous fluid in the alveolar spaces (arrows) and 
destruction of airways (arrowheads) in OVA-veh group when compared to naïve or 
OVA-res groups. Measurements of asthma-associated cytokines are shown for BALF (B) 
and serum (C). Asterisks (*) represent significance (p <0.05) difference for all 
experiments. ANOVA and post-hoc Tukey’s tests were performed to determine the 
significance (p<0.05) difference between the groups. 
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Figure 1.2. Resveratrol decreases T cell subpopulations in lungs of OVA-
administered mice. Resveratrol was used to treat OVA-induced asthma as described in 
Fig 1 legend.  Lung infiltrating inflammatory cells were stained by flow cytometry.  A) 
Shows a representative flow cytometric analysis of CD3+CD4+ and CD3+CD8+ T cells.  
Data presented in percentage in each Flow data represent the value of three independent 
experiments. Vertical bars represent total cell number/mouse (Mean+/- SEM) from 
multiple experiments. B) Shows a representative flow cytometric analysis of CD4+IL4+ 
Th2 cells. C) Shows a representative flow cytometric analysis of CD25+FoxP3+ Tregs 
gated on CD3CD4 cells. For B) and C) vertical bars represent percentage of cells/mouse 
(Mean+/- SEM) from multiple experiments. Asterisks (*) represent significance (p <0.05) 




Figure 1.3. Resveratrol treatment alters miRNA profile in lung infiltrating cells. 
OVA-induced asthmatic mice were treated with resveratrol as described in Fig 1 legend.  
Lung infiltrating cells from naïve, OVA-veh and OVA-res groups were isolated and total 
RNAs including miRNAs were used to perform miRNA arrays. A) Heat map showing 
miRNAs expression profile with red representing upregulated while blue representing 
downregulated miRNAs.  B) Volcano Plot shows that OVA-res group has higher levels 
of downregulated miRNAs when compared to OVA-veh group.  C) Principal component 





Figure 1.4. Analysis of dysregulated miRNAs and regulation of Foxp3 and cytokine 
genes post resveratrol treatment. A) Ingenuity Pathway analysis was performed to 
analyze dysregulated miRNAs and identify target molecules.  B) Shows the alignment of 
targeted gene and miR-34a using miRNA.org software. qPCR was performed to validate 
of the expression of miR-34a (C) and its target gene FOXP3 (D), transcription factor 
GATA3 (E), cytokine IL-13 (F) and cytokine IL-10 (G). Data are shown as Mean +/- 
SEM of triplicates and asterisks (*) represent significance (*p <0.05, **p <0.01, *** p 
<0.001, ****p <0.0001). Significance of data was determined using ANOVA test and 





Figure 1.5. Resveratrol treatment leads to induction of FOXP3+ cells in the lungs:  
Immunofluorescence and Immunohistochemistry were performed to determine the 
expression of FOXP3 in lung tissues and FoxP3 expression in the cells was assessed 
using corrected total cell fluorescence (CTCF) and ImageJ software. A) Shows the 
expression of FOXP3 in lung tissues. The data in vertical bars represent Mean+/- SEM of 
10 random spots analyzed. Significance (*p <0.05) of FoxP3 expression between the 
groups were analyzed using Student’s t-test.   B) Shows FoxP3 expression in lung tissues 
by performing Immunoprecipitation. The data represented as Mean+/- SEM of random 3-
5 spots that were analyzed. Significance (*p <0.05) in FoxP3 expression was detected 
using Student’s t-test. 
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Figure 1.6. The effect of transfection of miR-34a mimic and inhibitor on Foxp3 gene 
expression. qPCRs were performed to determine the expression of miR-34a and FoxP3 
post transfection of splenocytes with miR-34a mimic and miR-34 inhibitor. A) Shows the 
expression of miR-34a and B shows the expression of FoxP3 in splenocytes post 
transfection.  The data presented as vertical bars represent Mean+/- SEM of triplicates.  
Significance (p* <0.05) of miR-34a and FoxP3 expression was determined using 
ANOVA test and Tukey`s-hoc test. 
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ROLE OF MIRNA IN THE REGULATION OF CANNABIDIOL-
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2.1. Abstract 
Neuroblastoma (NBL) is one of the most common childhood cancers that 
originate from the immature nerve cells of the sympathetic system. Studies with NBL 
cancers have also shown that miRNAs are dysregulated and may play a critical role in 
pathogenesis. Cannabidiol (CBD) is a non-psychoactive compound found in marijuana 
which has been previously shown by our laboratory and others to induce apoptosis in 
cancer cells. However, there are no studies reported to test if CBD mediates these effects 
through regulation of miRNA. In the current study, therefore, we investigated if CBD 
induces apoptosis in human NBL cell lines, SH SY5Y and IMR-32, and if it is regulated 
by miRNA. Our data demonstrated that CBD induces apoptosis in NBL cells through 
activation of serotonin and vanilloid receptors. We also found that caspase-2 and -3 
played an important role in the induction of apoptosis. CBD also significantly reduced 
NBL cell migration and invasion in vitro. Furthermore, CBD blocked mitochondrial 
respiration and caused a shift in metabolism towards glycolysis. CBD altered the 
expression of miRNA specifically, down-regulating hsa-let-7a and upregulating hsa-mir-
1972. Downregulation of let-7a increased expression of target caspase-3, and growth 
arrest specific-7 (GAS-7) genes. Upregulation of hsa-mir-1972 caused decreased 
expression of BCL2L1 and BCL2 genes. Together, our studies suggest that CBD-
mediated apoptosis in NBL cells is regulated by miRNA. 
2.2. Introduction 
Neuroblastoma (NBL) is a tumor characterized by heterogeneity and variable 
clinical outcomes arising from premature sympathetic neurons, and is most commonly 
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encountered in infants and young children [123]. According to the American Cancer 
Society, the 5-year survival rate for NBL is less than 50% after treatment with surgery 
followed by chemotherapy or radiotherapy. These outcomes are likely due to both the 
relapse of tumor and the cytotoxic side effects of intensive therapy.  Although variable 
treatment strategies have been established and have been effective in treating the tumor, 
post-intervention rates remain constant due to side effects of treatment [124].  
Cannabidiol (CBD) is a member of a group of compounds known as cannabinoids 
that are found in the plant, Cannabis sativa [125]. Such cannabinoids are chemically 
identical to endogenous cannabinoids[126]. Cannabinoids act primarily through 
activation of CB1 or CB2 receptors [126]. Both receptors are G-protein coupled receptor 
but the CB1 receptors are predominantly expressed in the neurons whereas the CB2 
receptors are mainly located in the immune cells [125]. CBD is free of psychoactive 
effect because it doesn’t have a significant affinity for both receptors [127].   
Our laboratory was one of the first ones to demonstrate that cannabinoids can 
induce apoptosis in cancer cells and when injected into mice, could cause syngeneic 
tumor rejection [128]. Since this seminal observation, a large number of publications 
have confirmed and extended these studies to a variety of tumors that express 
cannabinoid receptors. Interestingly, we and others have shown that CBD can also induce 
apoptosis in many types of cancers such as breast, glioma, glioblastoma, and leukemia 
[129-133].While different signaling pathways have been identified that trigger apoptosis 
in cancer cells following treatment with CBD, whether such events are mediated by 
microRNA (miR) has not been previously investigated. 
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MiRNAs are small non-coding RNAs which are involved in RNA silencing and 
post-transcriptional regulation of gene expression. MiRNAs play a key role in cancer 
biology and help determine the nature of the tumor, prognosis and response to treatment.  
The first report on role of miRNA in cancer was suggested by identifying miR-15a/16-1 
cluster deletion in human chronic lymphocytic leukemia [134]. This deletion induced 
overexpression of the anti-apoptotic B-cell lymphoma 2 (BCL2), which was a target of 
these miRNAs [134]. Specifically, studies with NBL cancers have also shown that 
miRNAs are dysregulated and may play a critical role in the pathogenesis.  For example, 
the miR-17-5p-92 cluster was over-expressed in NB cells lines exhibiting overexpression 
of MYCN [135]. Interestingly, in vitro or in vivo treatment of MYCN-amplified and 
therapy-resistant neuroblastoma cells with antagomir-17-5p led to inhibition of growth of 
these cancer cells through activation of apoptosis [135]. MiRNA dysregulation has also 
been associated with development of resistance to therapies. For example, during the 
development of resistance, cancer cells expressed decreased levels of miRNAs, such as 
miR-200c and miR-579-3p, two potent oncosuppressors [136, 137]. Thus, restoration of 
their expression led to increased efficacy of drugs that targeted MAPK pathway.  
We previously showed that CBD can induce apoptosis in human leukemic cells in 
vitro and when injected into mice, cause syngeneic tumor regression [133]. In this model, 
treatment of cancer cells with CBD increased the levels of reactive oxygen species (ROS) 
and NAD (P)H oxidases Nox4 and p22(phox), while causing a decrease in the levels of p-
p38 mitogen-activated protein kinase [133]. Other studies have also shown that CBD 
induces apoptosis via inhibition of Akt/mTOR pathway [138] and this relates to the fact 
that Akt is overexpressed in many human cancers and is responsible for their resistance to 
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apoptosis [139]. Despite such studies, no previous studies have explored the role of 
miRNA in CBD-mediated induction of apoptosis in cancer cells.  To that end, in the 
current study we identified miRNA that are modulated by CBD and studied their 
potential role in inducing apoptosis in NBL cells.  
2.3. Material and methods 
2.3.1. Cell lines and reagents 
Human NBL cell lines SH SY5Y and IMR-32 were purchased from ATCC 
(American Type Culture Collection, Manassas VA) and were grown in DMEM; 
Dulbecco`s Modified Eagle`s Medium (ThermoFisher Life Technologies, Grand Island, 
NY, USA) supplemented with 10% heat-inactivated fetal bovine serum (Atlanta 
Biologicals, Lawrenceville, GA), 100 units/ml penicillin, 100 μg/ml streptomycin, in 
5mM Glutamine (ThermoFisher Life Technologies, Grand Island, NY, USA). Cell 
cultures were maintained in a humidified incubator set to 37ᴼC and 5% CO2. CBD was 
purchased from Cayman Chemicals, reconstituted in DMSO at a concentration of 20 
mg/ml, aliquoted and stored in -20 ͦC. Immediately before adding CBD to cells, it was 
diluted in serum-free DMEM at a concentration of 5 and 10 µM. The vehicle group 
received DMSO at the same dilution. Caspase inhibitors: caspase-2 (Z-VDVAD-FMK-
cat.no.FMK003), caspase-3 (Z-DEVD-FMK-cat.no. FMK004), caspase-8 (Z-IETD-
FMK-cat.no.FMK007), and caspase-9(Z-LEHD-FMK-cat.no.FMK008) were purchased 
from R&D system (Minneapolis, MN, USA). They were reconstituted in DMSO, 
aliquoted and stored at -20 ͦ C at a concentration of 100 µM. Just before treatment of the 
cells, each one of caspase inhibitors was diluted in complete DMEM at a concentration of 
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50 µM. Receptor antagonists SR144528 (CB2), AM251 (CB1), ML-193 (GPR-55), 
A784168 (TRPV1), BADGE (PPAR-γ), and MDL100907 (5-HT2A) were purchased 
from TOCRIS (Minneapolis, MN, USA). DeadEnd Colorimetric TUNEL kit (Cat. no. 
G7360) was purchased from Promega (Madison, WI, USA). Floroblock inserts (Cat.no. 
351158) were purchased from Corning (Tewksbury, MA, USA). Matrigel coated 
invasion chambers were purchased from VWR (Randor, PA, USA). Seahorse plates and 
media were purchased from Agilent Technologies (Santa Clara, CA, USA). 
2.3.2. Light Microscopy Analysis 
NBL cells were seeded in a 6-well plate (Corning, Tewksbury, MA, USA) 
overnight to allow them to adhere to the bottom of the plate. Next day, the medium was 
replaced by a serum-free medium containing either DMSO (vehicle), 5 or 10 µM CBD. 
After 24 h, the cells were visualized for cell morphology and viability under the light 
microscope Olympus SZX2 stereo microscope (Center Valley, PA).  
2.3.4. DeadEnd™ Colorimetric TUNEL System 
NBL cells were plated in a 6-well plate, treated with either DMSO (vehicle) or 1 
µM or 10 µM CBD in a serum-free medium for 24 h. Following manufacturer protocol, 
cells were washed with PBS, fixed with 4% paraformaldehyde, and permeablized with 
0.2% Triton X100. Cells were then equilibrated and labelled with Terminal 
deoxyneocleotidyl Transferase (TdT), and the reaction stopped by blocking buffer 
(supplied with the kit). Cells were stained with HRP-labelled streptavidin to be visualized 
under bright field conditions using Cytation 5 (Bio-Tek). Dead cells that stained brown 
were counted by Cytation 5 software and expressed as apoptotic cell number/field. 
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2.3.5. Annexin-PI and flow cytometry 
We assessed the level of apoptosis by using the FITC Annexin-V Apoptosis 
Detection Kit with PI from Biolegend (San Diego, CA). Cells were plated in a 12-well 
plate at a density of 2.5x10
6
 cells/well. The following day, cells were treated for 24 h 
either with DMSO, 5 or 10 µM CBD in serum-free medium. Cells then were stained with 
Annexin-V and PI, and analyzed using a FC500 Beckman Coulter flow cytometer 
(Indianapolis, IN, USA). For caspase inhibition, cells were treated with either DMSO 
(vehicle), 5 or 10 µM CBD in a serum-free medium. Cells were treated by 50 µM of 
caspase-2, caspase-3, caspase-8 or caspase-9 inhibitors in complete medium for one hour 
prior to treatment with CBD in serum-free medium. Cells then were harvested, washed, 
and stained for Annexin-V-PI for flow cytometry analysis. 
In order to detect receptors through which CBD acts, we plated SH SY5Y cells 
(1x10
5 
cell/well) in a 24-well plate overnight. Next, cells were treated for one hour with 
10 µM of AM251 (CB1 receptor antagonist), SR144528 (CB2 receptor antagonist), 
BADGE (PPAR-γ receptor antagonist), ML-193 (GPR-55 receptor antagonist), A784168 
(TRPV1 receptor antagonist), or MDL 100907 (5-HT2A receptor antagonist) followed by 
10 µM CBD in serum-free medium for 24 h. Cells then were collected, washed, and 
stained with AnnexinV-PI for flow cytometry analysis. 
2.3.6. Microarray and miRNA pathway analysis 
Microarray analysis was done by using an Affymetrix array version 4.0, in order 
to show the integrated mature miRNA in CBD-treated cells compared to the vehicle ones, 
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as detailed in our previous report [140]. According to manufacturer`s recommendation, 
60 ng/µl of mature miRNA was purified and HSR hybridized with biotinylated Flash Tag 
(Affymetrix, Santa Clara, CA). The log intensity values were measured by Affymetrix 
system and files were analyzed using genome expression console. The files were 
uploaded to Transcriptome Analysis Console (TAC) from Affymetrix in order to 
determine miRNA fold changes and p values. Fold change threshold for up- or 
downregulated miRNA was set to ≥ 2 or ≤ -2 and selected for further analysis using 
Ingenuity Pathway Analysis (IPA) from Qiagen. The Venn diagram for the assigned 
miRNAs was done using the Venn diagram maker 
(http://bioinfogp.cnb.csic.es/tools/venny/). 
2.3.7. Quantitative real-time PCR (qRT-PCR) 
qRT-PCR analysis was performed as detailed previously [141].  Total RNA was 
collected from SH SY5Y cells using the miRNeasy kit (Qiagen) per the manufacturer`s 
guidelines. Complementary DNA (cDNA) was reverse transcribed by using the miScript 
cDNA synthesis kit (Bio Rad) following the manufacturer`s recommended protocol. SSO 
SYBR Green (BioRad) was used on CFX context (BioRad) to perform qPCR. Human 
GAPDH was used as a control gene. Primers were designed in IDT DNA technologies 
according to the sequences found in Primers Bank (Harvard Medical School). We 
performed the PCR on the following protocol: 39 cycles for PCR as follows: 30 sec 98ᴼC 
(denaturation step), 60 sec at 60ᴼC (annealing step) and 60 sec at 72ᴼC (extension step, 
followed by incubation for 10 minutes at 72ᴼC. We assessed the expression of target 
miRNAs and the results were normalized to Snord 96A miRNA using a SYBR Green 
PCR kit from Qiagen. Primer sequences are given in the following Table: 
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2.3.8. miRNA- mimics and inhibitor transfections:   
Studies using miRNA mimics and inhibitors were performed as detailed in our 
previous studies [142-144] .  SH SY5Y cells were plated at a concentration of 4x10
5 
cells/well in a 24-well plate overnight. The next day, cells were treated with mock, hsa-
let-7a-mimic, or hsa-let-7a inhibitor for 24 h. The total RNA was collected from SH 
SY5Y cells using the miRNeasy kit (Qiagen) per the manufacturer`s guidelines. cDNA 
was synthesized using miScript cDNA synthesis kit (BioRad) followed by qPCR for 
genes of interest identified by Ingenuity Pathway Analysis map (IPA). After 24 h, RNA 
was collected for further analysis of miRNA and gene expression by qPCR as described.  
2.3.9. Western blot 
SH SY5Y cells were plated at a density of 2.5x10
5
 cells/well in a 6-well plate 
overnight. The next day, cells were treated either with DMSO (vehicle) or CBD 10µM in 
serum free medium for 6 h. Cells then were harvested, washed with PBS, and the protein 
was isolated using RIPA (radioimmunoprecipitation) lysis buffer (Santa Cruz). Twenty-
five micrograms of the protein was loaded on 10% Tris-Glycine gels  (Bio Rad) subjected 
to SDS-PAGE separation at 50V for 1 h and then at 80V for 2 h. The protein was 
transferred to nitrocellulose paper using iBlot2 from Invitrogen (Grand Island, NY, USA) 
at voltages: 20V for 1 minute, 23V for 4 minutes and 25V for 4 minutes. The membrane 
was blocked in 5% nonfat dry milk in TBS. The membrane was then labelled with 
antihuman PTEN and Akt antibodies from Santa Cruz (diluted 1:100). Secondary HRP-
conjugated antibodies (Cat.no. ab6721) (Abcam) were diluted 1:1000. GAPDH (Santa 
Cruz) served as a reference protein diluted at 1:2000 in 5% nonfat dry milk in TBS. ECL 
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substrate (Thermo fisher) was added to nitrocellulose paper for 3 minutes on the shaker 
and then photographed using an X-ray film developer. The density was measured by 
ImageJ from NIH. 
Protein was collected from SHSY 5Y cells transfected with hsa-let-7a 48 h, the 
level of caspase-3 protein (1:500) (Abcam), γ-tubulin (Cell Signaling)(1:2000) served as 
a reference protein in this experiment using the protocol described above. Secondary 
HRP-conjugated antibody was bought from (Abcam) and was used in a concentration of 
1:2000. Cellulose membrane was stained with WesternSure Chemiluminescent substrate 
(LI-COR). Then, protein images were detected using C-Digit scanner (LI-COR).  Image J 
software was used for analysis of the results, and the quantity of protein was measured 
after subtraction of the background by normalization to the housekeeping gene. The 
protein level of caspase-3 was calculated relative to corresponding mock level. 
2.3.9. Migration and Invasion Assays 
Migration of NBL cells was evaluated by trans-well chambers with floro-block 
inserts (Corning, Tewksbury MA, USA). According to the manufacturer`s guidelines, the 
chambers were inserted in a 24-well cell culture plates. The cells were stained with 
CFDA (Thermo Fisher Life Technologies, Grand Island, NY, USA). NBL cells were 
treated with DMSO or 10 µM CBD in a serum-free medium for 6 h. Treated cells were 
harvested, washed, and counted. Cells (3.5x10
5
) in 200 µl of serum-free medium were 
added to each chamber. We added 750 µl of the complete medium to the bottom of the 
plate. Cells were incubated for 24 h to assess cell migration through the membrane. The 
inserts were then washed, cells on the upper membrane were removed by swab and the 
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remaining cells of the bottom of the insert were then visualized and counted by Cytation 
5 (Bio-Tek, Winooski, VT, US). 
Cell invasion was assessed using matrigel coated Corning inserts (Tewksbury 
MA, USA), per the manufacturer`s recommendation.  Cells were plated in 24-well plates, 
stained with CFDA (ThermoFisher Life Technologies, Grand Island, NY, USA), washed 
with PBS, and treated with either DMSO or 10 µM CBD in serum-free medium for 6 h. 
Cells were then harvested, washed, and counted to be plated at a density of 3.5x10
5 
cells/ 
well in 350 µl of the serum-free medium. 750 µl of the complete medium was added in 
each well. Cells were incubated for 24 h at 37 ͦC. The inserts were washed, swabbed to 
remove the non-invading cells and visualized by the Cytation 5 inverted fluorescent 
microscope (BioTek, Winooski, VT, US). 
2.3.10. Metabolic Assay for determination of extracellular acidification rate (ECAR) 
and oxygen consumption rate (OCR) 
SH SY5Y cell lines were plated in 8-well Seahorse XFp Analyzer plates and 
allowed to adhere overnight. Cells were then treated either with DMSO (Vehicle) or 
10µM CBD in a serum-free DMEM for 6 h and are washed with XF medium per 
manufacturer`s recommendations. The Seahorse XFP was used to analyze the results of 
glycolytic stress and mitochondrial stress. 
2.3.11. Statistical Analysis of Data:  
Differential (upregulated or downregulated) expression of miRs was analyzed 
using 2-sample t-test method as described [145]. The microarray data were analyzed for 
significance using Kaplan-Meier method. Student’s t-test was used for comparing the 
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CBD-treated group to vehicle controls.  Multiple comparisons were made using ANOVA 
(one-way analysis of variance) test and post-hoc Tukeys’s test.  p < 0.05 was considered 
to be statistically significant.  All experiments were repeated at least twice.   
2.4. Results 
2.4.1. CBD induces apoptosis in NBL cell lines, SH SY5Y and IMR-32, through 
activation of caspase-2 and caspase-3. 
To examine the morphological effects of CBD on SH SY5Y and IMR-32 NBL 
cell line, we visualized them by bright field microscopy at 20X magnification. Apoptotic 
signs were assessed for clumping, blebbing, and shrinking. In contrast to the vehicle 
group, CBD-treated cells displayed elevated apoptotic rates (Fig 1A).  DeadEnd  
Colormetric TUNEL assay showed a significant increase in the number of positively 
stained (brown) cells in 10 µM CBD-treated cells when compared to the vehicle CBD-
treated groups; p <0.001 (Fig 1B &C). Flow cytometry analysis of SH SY5Y and IMR-
32 showed a significant increase in the number of the cells stained with AnnexinV (early 
apoptosis) and both Annexin-V and PI (late apoptosis) in 5 and 10 µM CBD treated 
group when compared to vehicle controls.  Also, 10 µM CBD caused significantly higher 
apoptosis when compared to 5 µM CBD treated cells (Fig1 D-F). 
Flow cytometry analysis was performed to investigate which caspases mediate 
CBD-induced apoptosis. Annexin-V-PI staining showed significant reduction in 
apoptosis in cells incubated with CBD and pre-treated with caspase-2 and caspase-3 
inhibitors when compared to CBD+vehicle controls (Fig 1G, H) In contrast, Caspase 8 
and 9 inhibitors failed to cause significant inhibition in apoptosis.   
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2.4.2. Identification of receptors through which CBD induces apoptosis  
To determine which receptors play a role in CBD-induced apoptosis, we utilized 
several receptor antagonists followed by staining and flow cytometric analysis of 
apoptotic cells.  There was a significant reduction in the percentage of total apoptotic 
cells induced by CBD in samples pre-treated with GPR55 antagonist (ML-193), TRPV1 
antagonist (A784168), or 5-HT2A receptor antagonist (MDL100907) when compared to 
CBD+vehicle group (Fig 2 A-C). However, CB1 antagonist (AM251), CB2 antagonist 
(SR144528), or PPAR- -mediated 
apoptosis.  These data suggested that CBD may induce apoptosis through activation of 
GPR-55, 5-HT2A and TRPV1 receptors.  
2.4.3. Role of miRNA in the regulation of CBD-mediated apoptosis  
We performed miRNA array in CBD-treated SH SY5Y cells to elucidate the role 
of miRNA in CBD-induced apoptosis.  Volcano plots and heat map showed that CBD 
treatment induced changes in the miRNA profile (Fig 3A and B). A Venn diagram 
demonstrated that SH SY5Y cells treated with 10 µM CBD induced upregulation of 50 
miRNAs and downregulation of 85 miRNAs (Figure 3C). The dysregulated miRNAs 
with fold change ≥2 or ≤-2 were uploaded to Ingenuity Pathway Analysis (IPA) from 
Qiagen. IPA software showed that hsa-let-7a was highly downregulated (-12 fold) and 
was targeting caspase-3, GAS-7, and DIABLO genes (Figure 3D). In contrast, CBD 
treatment caused upregulation of hsa-miR-1972 (>2 fold) that targeted BCL2 and 
BCL2L1 genes (anti-apoptotic mitochondrial proteins). Principal Component Analysis of 
3 independent samples showed distinct clustering of miRNA profiles in vehicle- and 
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CBD-treated groups (Fig 3E).  Because down-regulation of the expression of miRNA 
leads to induction of the target gene while its upregulation leads to gene silencing, our 
data suggested that the changes in miRNA induced by CBD may collectively promote 
apoptosis.   
2.4.4. CBD induced alterations in miRNA expression and their effect on target genes 
involved in apoptosis. 
We performed qRT-PCR for the validation of miRNA and genes identified by 
IPA software. Gene alignment software predicted that miR-hsa-let-7a targeted Caspase-3 
and GAS-7 genes while miR-hsa-1972 targeted BCL2 and SIRT2 genes (Fig 4A).  We 
found that CBD treatment of cells led to significant downregulation of miR-hsa-let-7a 
with consequent increase in Caspase-3 and GAS-7 (Fig 4A). On the other hand, hsa-miR-
1972 was significantly upregulated in CBD-treated group when compared to the vehicle, 
and the related genes, BCL2xL, SIRT2 and MYCN were significantly downregulated in 
CBD-treated group versus vehicle (Fig 4A).  
To further validate the role of miRNA in the regulation of aforesaid target genes, 
we performed transfections of hsa-let-7a mimic or inhibitor in NBL cell line. In this 
experiment, we found that transfection of hsa-let-7a inhibitor significantly induced 
caspase-3 and GAS-7 expression when compared to mock control (Figure 4B). 
Transfection of a hsa-miR-1972 mimic caused significant downregulation of BCL2L1, 
MYCN and SIRT2 when compared to mock control (Fig 4C). Protein levels of caspase-3 
using western blotting shows that the expression of caspase-3 in the cells transfected with 
hsa-let-7a inhibitor was 4.7 folds higher than the cells transfected with the mock control.  
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2.4.5. CBD targets genes involved in cell migration, invasion, metabolism and 
apoptosis. 
We examined other potential genes that are regulated by altered expression of 
miRNA and found that P53 and AKT1 expression was significantly downregulated while 
the expression of MDM2 and PTEN was significantly higher in the CBD treated group 
when compared to vehicle (Fig 5A).  SDS-PAGE and subsequent western blot were 
performed to validate gene expression data. Our analysis on whole cell lysate 
demonstrated the CBD-treated NBL cell line showed decreased AKT and increased 
PTEN proteins when compared to the vehicle control (Fig 5B) 
2.4.6. CBD inhibits cell migration, invasion and mitochondrial respiration of NBL 
cells. 
One important feature of recurrent malignant diseases is their ability to migrate, 
invade, and shift their metabolism. For this reason, we measured the ability of CBD to 
inhibit cancer migration, invasion and metabolism.  We found that CBD was able to 
significantly inhibit SHSY 5Y (Fig 6A &B), IMR-32 cell migration (Fig 6 C&D) and 
invasion through matrigel (Fig 6 E&F). Additionally, CBD altered mitochondrial 
respiration, particularly maximal respiration, measured via oxygen consumption rate 
(OCR), which was significantly reduced after CBD treatment (Fig 7B). On the other 
hand, extracellular acidification rate (ECAR) that measures the rate of glycolysis, did not 
change (Fig 7A).  As a result, we believe that CBD treatment inhibited the mitochondrial 





Our laboratory was one of the first one to discover that cannabnoids can induce 
apoptosis in cancer cells through activation of cannabinoid receptors [128].  This has led 
to additional studies on the effect of cannabinoids in the treatment of cancer   [146-153]. 
CBD is a non-psychoactive cannabinoid that has been reported to have the potential 
efficacy to treat breast, prostate, glioma, lung and cervical cancers [130, 131, 152, 154]. 
Neuroblastoma (NBL) constitutes one of the most common solid cancers in children.  
While chemo, radiation, and immunotherapy are used to treat NBL, children with this 
cancer have poor outcomes.  Also, while CBD has been shown to kill NBL cells [146], 
the precise molecular pathways remain further elucidation.  Importantly, there are no 
previous studies delineating the role of miRNA in the anti-cancer properties of CBD.  
Such studies are important because they will also help identify additional miRNA targets 
that can be used to treat NBL. 
Initially, we treated SH SY5Y and IMR-32 NBL cell lines with 5 and 10 µM/L of 
CBD in serum-free medium. Within 18 h, NBL cells showed apoptosis as seen in our 
assay. We used caspase inhibitors (caspase-2, -3, -8, and -9) to explore the role of 
caspases and found that apoptosis in NBL cells was dependent on caspase-2 and 3 but not 
8 and 9. Caspase 8 is known to regulate death cell receptor (extrinsic) pathway, while 
Caspase-9 controls the mitochondrial pathway [155]. Interestingly, when we looked at 
the role of Caspase-2, which is similar to caspase-9 in structure, we found that inhibition 
of Caspase-2 attenuated CBD-induced apoptosis. This finding is consistent with previous 
studies in which it was shown that Caspase-2 may play a key role in apoptosis induced by 
metabolic imbalance, DNA damage, and endoplasmic reticulum (ER) stress [156].  
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Previous studies have shown that apoptosis induced by indoles is also mediated by 
Caspase-2 but independent of Caspase-8 and -9 [142].  Caspase-2 is one of the most 
evolutionarily conserved caspases, and whether or not Caspase-2 fits the role of a 
traditional initiator or effector caspase, or both, remains to be established.  However, 
Caspase-2 can engage the mitochondrial pathway to trigger apoptosis involving caspase-
independent death effectors apoptosis-inducing factor (AIF) and endonuclease G [157].  
Such a mechanism can explain how CBD can engage Caspase-2 in the induction of the 
mitochondrial pathway, independent of caspase-9. Caspase-2 is also the sole caspase 
known to translocate from the cytosol to the nucleus, thereby suggesting that it is 
involved in cellular processes other than apoptosis [158] . 
CBD does not have much affinity towards CB1 and CB2 receptors because of 
which it is not psychoactive.  In the current study, we also noted that CBD-mediated 
apoptosis was not blocked by CB1 and CB2 antagonists.  However, we noted that CBD 
may induce apoptosis through activation of GPR-55, 5-HT2A and TRPV1 receptors, 
based on blocking studies. CBD is well established to bind and function primarily 
through activation of TRPV1 or vanilloid receptors [159]. Researchers have also 
documented that CBD uses vanilloid and 5-hydroxy tryptamine receptors to induce 
autophagy or prevent cancer growth [148-150]. Activation of the TRPV1 receptor has 
been shown to increase Ca
++
 in the cytoplasm followed by ER stress and apoptosis in 
gliomas [160] and in prostate cancer [161].  GPR-55 is an orphan G-protein coupled 
receptor expressed in the brain and in cell cultures, and is known to bind to certain 
cannabinoid ligands [162].  However, the role of GPR-55 in CBD functions remains 
unclear.   In an earlier study, we found that CBD could induce apoptosis in human 
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leukemic cells. CBD increased reactive oxygen species (ROS) production as well as 
NAD(P)H oxidases Nox4 and p22 (phox) [133]. CBD also caused a decrease in the levels 
of p-p38 mitogen-activated protein kinase, which could be blocked by treatment with a 
CB2-selective antagonist or ROS scavenger [133]. These data and the current study 
suggested that CBD-mediated apoptosis in cancer cells may involve different pathways 
and receptors. 
Gene expression is regulated by different mechanisms including miRNA 
regulation, which constitute small protein non-coding, 20-25 nucleotides long [163]. 
Comparisons of miRNA expression in malignant and normal cells highlight the 
importance of cancer-related miRNAs. Additionally, miRNAs may function as 
oncogenes or tumor-suppressor genes [164]. Previous studies have shown that miRNAs 
have a critical role in cell growth, differentiation, and apoptosis [165]. We found that let-
7a was significantly down-regulated in CBD treated cells versus vehicle.  It has been 
shown that let-7a is a tumor suppressor in colon [166] and prostate cancer [167]. Other 
studies reported that let-7a targets caspase-3 and thus, down-regulation of let-7a increases 
drug-induced apoptosis [168]. In the current study, we found that downregulation of hsa-
let-7a could upregulate caspase-3 gene expression in CBD-treated SH SY5Y cells. 
Furthermore, hsa-let-7a inhibition led to induction of GAS-7, a member of protein family 
known as PCH (Pombe Cdc 15 homology) which is mainly localized in neurons and is 
responsible for differentiation and survival [169]. The potential role of GAS-7 in cancer 
or apoptosis remains to be determined.  In addition to let-7a downregulation, we found 
that CBD caused upregulation of hsa-miR-1972, which based on gene alignment scores, 
was predicted to bind Sirt-2 and BCL2L1 genes. Downregulation of Sirt-2 reduces 
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MYCN gene expression and results in apoptosis in a neuroblastoma cell line [170]. 
Therefore, we propose that upregulation of hsa-miR-1972 resulted in the downregulation 
of both genes and induced death in NBL cells. Both genes have been extensively studied 
in cancer and have shown to be regulated by several miRNA [171-174].  To confirm our 
finding that CBD caused a shift in miRNA expression, we transfected let-7a mimic and 
inhibitor into NBL cell lines. Our data showed that gene expression of CASP3 and GAS-
7 was significantly higher in the cells transfected with hsa-let-7a-inhibitor when 
compared to those transfected with let-7a mimic. In addition, caspase-3 protein 
expression was higher in SHSY 5Y cells transfected with hsa-let-7a inhibitor as 
compared to those transfected with mock control. 
We further assessed the expression of MYCN, the primary oncogene in NBL, and 
demonstrated that its gene expression by qRT-PCR was significantly downregulated and 
associated with downregulation of p53 gene (a transcriptional target of MYCN).  The 
effect on p53 may also result from MDM2, a negative regulator of p53 [175, 176].  Also, 
PTEN tumor suppressor protein inhibits activation of Akt [177], which restricts MDM2 
to the cytoplasm.  Associations between MYCN and p53 were recently confirmed [178]. 
Our western blot analysis showed that the protein expression of PTEN was significantly 
upregulated in the CBD-treated group while that of Akt was significantly downregulated 
when compared to the vehicle. We also found that six h after CBD treatment there was 
significant inhibition of SH SY5Y cell migration and invasion, and this may be mediated 
through AKT-signaling. PTEN activity has been shown to inhibit cell migration and 
invasion [179-181]. Additionally, PTEN may play a major role in apoptosis as well by 
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inhibiting AKT signaling [182-184]. Our findings suggest that CBD induces apoptosis in 
NBL cell line by inhibition of Akt protein mediated by PTEN upregulation. 
We used Seahorse XFp analysis to investigate the CBD`s effect on the 
metabolism in SH SY5Y cells. Metabolic activity was assessed by mitochondrial 
respiration, which was significantly disrupted after 6 h of treatment with 10 µM CBD. 
However, SH SY5Y cells shifted their metabolism towards glycolysis to skip the effects 
of CBD on their metabolism, an effect known as Warburg effect [185]. The Warburg 
effect is the ability of cancer cells to shift the generation of ATP from oxidative 
phosphorylation to glycolysis and can be regulated by the AKT/mTOR pathway [186, 
187]. Our data suggested the metabolic dysfunction in CBD-treated cells is through the 
AKT-dependent mechanism. In addition, downregulation of MYCN expression has been 
shown to be responsible for shutting down glycolysis [188]. Early response of SH SY5Y 
by significant reduction of mitochondrial respiration has been noted before with other 
neurotoxins [189]. Together, the current study suggests that CBD alters the expression of 
several miRNA that target critical signaling pathways implicated in apoptosis, migration 
and invasion, and metabolic functions in NBL cells. 
2.6. Statistical analysis: 
One-way ANOVA with post-hoc Tukey`s test was used to compare between three 
groups. Student’s t-test was used to compare two groups. In all experiments, data were 
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Table 2.1 Primer sequences for qPCR analysis of SHSY 5Y cells and associated miRNA. 
 
Casp-3 forward 5`-GAAATTGTGGAATTGATGCGTGA-3` 
Casp-3 reverse 5`-CTACAACGATCCCCTCTGAAAAA-3` 
GAS-7 forward 5`-CATCGCCAAGCAAAAAGCAGA-3` 
GAS-7 reverse 5`-AGCCCAGAAGTAGTCGCAGT-3` 
BCL2L1 forward 5`-GACTGAATCGGAGATGGAGACC-3` 
BCL2L1 reverse 5`-GCAGTTCAAACTCGTCGCCT-3` 
Sirt2 forward 5`-TGCGGAACTTATTCTCCCAGA-3` 
Sirt2 reverse 5`-GAGAGCGAAAGTCGGGGAT-3` 
p53 forward 5`-GAGGTTGGCTCTGACTGTACC-3` 
p53 reverse 5`-TCCGTCCCAGTAGATTACCAC-3` 
MYCN forward 5`-ACCCGGACGAAGATGACTTCT-3` 
MYCN reverse 5`-CAGCTCGTTCTCAAGCAGCAT-3` 
PTEN forward 5`-TTTGAAGACCATAACCCACCAC-3` 
PTEN reverse 5`-ATTACACCAGTTCGTCCCTTTC-3` 
AKT1 forward 5`-TCCTCCTCAAGAATGATGGCA-3` 
AKT1 reverse 5`-GTGCGTTCGATGACAGTGGT-3` 
MDM2 forward 5`-GAATCATCGGACTCAGGTACATC-3` 
MDM2 reverse 5`-TCTGTCTCACTAATTGCTCTCCT-3` 
GAPDH forward 5`-GGAGCGAGATCCCTCCAAAAT-3` 






Figure 2.1. Treatment with CBD induces apoptosis in neuroblastoma cell lines. SH 
SY5Y and IMR-32 neuroblastoma cell lines were treated with vehicle or CBD in serum-
free medium for 24 hours. A) Bright field image showing that CBD induces significant 
morphological damage in neuroblastoma cells in a dose-dependent manner.   B) Tunnel 
assay for SH SY5Y after treatment with either vehicle or CBD (1 or 10 µM). The arrows 
are pointing to the nuclei of the dead cells which are stained dark brown with HRP-
labeled streptavidin. C) Bar diagram shows the number of apoptotic cells per field in B. 
Significance (p value <0.05) for the experiment was determined using one-way ANOVA 
and post-hoc Tukey`s test. D) Flow cytometry analysis of SH SY5Y and IMR-32 cell 
lines after 24 hours treatment with either vehicle or CBD (5 or 10 µM).  Cells in early 
apoptosis stain with Annexin-V only while those in late apoptosis are double-stained with 
Annexin-V and PI.  Panels E and F show the statistical analysis of data from multiple 
experiments for SH SY5Y and IMR-32 cell lines, respectively. G) Representative 
experiment in which SH SY5Y cells were treated with vehicle or 10 µM CBD+vehicle or 
CBD+caspase inhibitors and cells analyzed for apoptosis using Annexin V staining. H) 
Data from panel G in multiple experiments plotted.  All experiments were repeated three 
times.  Significance (p <0.05) for all experiments was calculated using one-way ANOVA 
and post-hoc Tukey`s test.  
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Figure 2.2. Identifying the receptors through which CBD induces apoptosis in SH 
SY5Y neuroblastoma cells.  SH SY5Y cells were plated overnight and then treated 
either with vehicle or receptor antagonist for 1 hour followed by 10 µM CBD.  Next, the 
cells were harvested and stained with Annexin-V- PI followed by flow cytometric 
analysis. The data from a representative experiment has been shown (Panel A) and data 
from multiple experiments have been plotted in the bar diagram (Panel B).  Panel C 
shows morphology of cells exposed to cultures as described in Panel A.  Significance (p 




Figure 2.3. MiRNA profile in SH SY5Y neuroblastoma cells following CBD 
treatment. Microarray analysis was done by using an Affymetrix array to identify 
miRNA in CBD-treated Pcells compared to vehicle controls.  (A) Volcano plot for up- 
and down-regulated miRNAs following treatment either with DMSO (vehicle) or 10 µM 
CBD (CBD). The upregulated miRNAs appear in red color while the down-regulated are 
shown in green dots using TAC software from Affymetrix. (B) Heat map for 
dysregulated miRNA following treatment with CBD (TAC software). The red color 
represents the upregulated miRNAs while the blue color represents the downregulated 
ones. (C) Venn diagram shows differentially regulated miRNA in the two groups.  D) 
Ingenuity Pathway Analysis displaying the relationship between the dysregulated miRNA 
and different target genes related to apoptosis. The panel shows how miRNA hsa-let-7a 
(green) and hsa-miR-1972 (red) may target apoptotic pathways.  E) Principal Component 
Analysis of 3 independent samples showing distinct clustering of miRNA profiles in 




Figure 2.4. Validation of miRNAs and their potential targets.  (A) SHSY 5Y cells 
were cultured with either DMSO or 10µM CBD as described in Figure 1 legend.  Next, 
qPCR was performed for the genes of interest according to Ingenuity Pathway Analysis 
map. (B) SH SY5Y cells were treated with either mock, hsa-let-7a-mimic or hsa-let-7a 
inhibitor for 24 hours. Next, qPCR was performed.  We validated that hsa-let-7a 
transfection was successful as shown in the first panel.  The next two panels show the 
levels of expression of caspase-3 and GAS7. C) SH SY5Y cells were treated with mock, 
hsa-mir-1972 mimic or hsa-mir-1972 inhibitor. Next, qPCR was performed.  First panel 
shows validation that hsa-mir-1972 transfection was successful.  The next three panels 
show the levels of expression of BCL2xL, Sirt-2, and MYCN. D) After transfecting 
SHSY 5Y with hsa-let-7a mimic and inhibitor, protein was obtained, and western blot 
was done to detect the level of caspase-3. The level of caspase-3 protein was 4.7 folds 
higher than the mock control. Significance (p <0.05) for all experiments was determined 




Figure 2.5. Effect of CBD on target genes involved in cell migration, invasion, 
metabolism and apoptosis. SHSY 5Y cells treated with vehicle or 10µM CBD were 
used to perform (A) qPCR or (B) Western Blots for the genes of interest according to 
Ingenuity Pathway Analysis map. In Panel A, significance (p <0.05) was determined 
using Student’s t –test. 
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Figure 2.6. CBD inhibits cell migration, invasion and mitochondrial respiration of 
neuroblastoma cells.  A) SH SY5Y cells C) IMR-32 cells were cultured with vehicle, 5 
µM, or 10 µM CBD and stained with Vybrant CFDA. Live cells were seeded per 
floroblock inserts of a 24-well plate. Cells were allowed to migrate for 24-hour.  Next, 
cells were visualized using Cytation 5 microscope.  Panel A and C show data from a 
representative experiment while Panel B and D show data from multiple experiments, 
respectively. E) SH SY5Y cells were cultured as in Panel A with vehicle, 5 µM, or 10 
µM CBD and live cells were seeded in matrigel-coated inserts for 24-well plate. Cells 
were allowed to migrate for 24-hour. Then cells were visualized using Cytation 5 
microscope. Panel E shows data from a representative experiment while Panel F shows 
data from multiple experiments.  Significance (p <0.05) for all experiments was done 





Figure 2.7. CBD alters mitochondrial respiration in neuroblastoma cells.  SH SY5Y 
cells were cultured overnight in a Sea-horse Analyzer plate. The following day, the cells 
were treated with either vehicle or 10 µM CBD, washed with Seahorse-specific medium, 
and placed in a Seahorse analyzer. (A) Analysis of glycolysis by ECAR determination. 
(B) Analysis of mitochondrial respiration by OCR analysis. Significance (p <0.05) for all 
experiments was determined using Student`s t-test. 
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CHAPTER 3
RESVERATROL TREATMENT IMPROVES LUNG FUNCTION IN A 
MOUSE MODEL OF OVALBUMIN-INDUCED ALLERGIC RESPONSE 
WHICH IS ASSOCIATED WITH REMODELING OF THE GUT AND 
LUNG MICROBIOTA COMPOSITION 
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3.1. Abstract 
The pivotal roles of the microbiota residing along mucosal surfaces, both local 
and distal to the afflicted site, have garnered an appreciation in the field of immunology 
when studying autoimmune disorders. In this study we focused on the bioactive molecule 
resveratrol (RES), a polyphenol compound derived from plants. Resveratrol is known for 
its multifaceted approach to combat autoimmune disorders via its anti-inflammatory, 
anti-microbial and anti-oxidative properties. In this study, we focused on the direct 
effects of resveratrol supplementation on the clinical symptoms of ovalbumin (OVA)-
induced murine allergic response, as well as the effects on bacterial composition of the 
pulmonary tract and the cecum, and on the expression of  tight junction-regulating genes 
in the lung epithelium. We found that resveratrol induced colonization of Akkermansia 
muciniphila in the lung tissue and Bacteroides acidifaciens in the colon of resveratrol-
treated OVA-stimulated mice, relative to VEH-treated mice. In addition, we found that 
RES induced significant changes in tight junction and PPAR-γ gene expression in 
pulmonary epithelium of OVA-stimulated mice treated with RES, when compared to 
those mice treated with VEH. We conclude that RES has promising efficacy in the 
treatment of asthma and its effect may be mediated by changes in gut-lung microbiome 
axis.   
3.2. Introduction 
Asthma is an incurable and chronic inflammatory disease mediated by excessive 
T helper lymphocyte type 2 (Th2) activation along the bronchial airways [190]. 
Excessive Th2 activation in asthmatic patients produces characteristic airway conduit 
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constriction affecting breathing function. Asthmatic pathology on the subcellular level is 
characterized by the excessive production of pro-inflammatory Th2 cytokines, such as 
IL-4, IL-5, and IL-13.  The triggered release of these cytokines during an asthma attack 
initiates a cascade of inflammatory responses along the barrier sites of the pulmonary 
system [190, 191]. Excess inflammation at the bronchial epithelium results in the 
mechanical disruption of tight junction molecules, compromising its barrier integrity. 
Asthma attacks compromise the airway epithelium and induce a positive feedback loop of 
inflammatory responses, in which excessive inflammation drives the exposure of 
basolateral receptors and sub-epithelial tissue layers to additional allergens via airway 
remodeling [192]. 
The role of the gut microbiome is highlighted by the proposed “hygiene 
hypothesis,” which correlates the antiparallel incidental increase of autoimmune diseases 
with the incidental decrease of infectious diseases in westernized societies [193, 194]. 
Incidence of asthma, along with other atopic diseases, has increased over recent decades 
and is thought to be, at least partially, linked to reduced exposure to microbial agents 
during development [39]. Several studies support the hygiene hypothesis by contrasting 
the constituents of the gut microbiota within allergic versus non-allergic infants in the 
first six months of life, prior to the development of atopic disorders, such as asthma [195-
197] . These studies demonstrate that, prior to the onset of atopic disorders, microbial 
dysbiosis, favoring a lack of beneficial short chain fatty acid (SCFA) producing 
commensal organisms, is correlated with the amelioration and prevention of autoimmune 
disorders [198-200]. SCFAs produced by fermentation of dietary fibers via resident 
microbiota have proven effective in the amelioration of autoimmune disorders through 
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the induction of T regulatory lymphocyte (Treg)-mediated tolerance. SCFAs drive the 
proliferation of Tregs by inhibiting histone deacetylase enzymes (HDACs) near the 
promoter region of the Treg master transcription factor, forkhead box P3 (Foxp3) gene 
[201]. Several extrinsic factors experienced in early life, such as maternal administration 
of antibiotics during pregnancy, maternal exposure to pets, delivery by caesarian section, 
and feeding with infant formula have lasting effects on the gut microbiota constituents 
and have been associated with the development of asthmatic symptoms [202]. The 
importance of lung microbiota composition has been highlighted in studies involving 
mice, whereby inoculation of commensal Escherichia coli species attenuates OVA-
induced airway inflammation [203]. The lung microbiota composition even plays an 
important role in the treatment of  established asthma symptoms, as seen in differential 
microbial compositions seen in the lungs of corticosteroid-resistant versus corticosteroid-
susceptible patients [204]. Analysis of lung microbiome revealed an enrichment in genera 
Haemophilus and Nisseria in corticosteroid-resistant population when compared to the 
steroid-responsive population. Further studies comparing house dust mite (HDM)-
induced asthma in specific pathogen free (SPF) and germ free (GF) mice identified a 
immunomodulatory role for lower airway commensal microbiota via the promotion of 
local tolerance through the induction of a specific set of Helios negative Tregs [205].  
Resveratrol, a widely studied and commercially available plant-derived bioactive 
polyphenol molecule, has been proven effective in attenuation of inflammatory responses 
in a variety of disorders due to its anti-inflammatory, anti-oxidative and anti-microbial 
properties [82, 206, 207] . Resveratrol’s anti-inflammatory properties are due primarily to 
Aryl Hydrocarbon Receptor (AHR)-mediated expansion of Tregs [208, 209]. AHR has a 
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pivotal role in the regulation of lymphocyte proliferation and can either drive or alleviate 
inflammation, dependent upon specific ligand [210, 211]. One mechanism by which the 
downstream effects of RES supplementation are carried out, is by the induction of Tregs 
which suppress effector functions of pro-inflammatory lymphocytes [77, 212]. RES also 
possesses the ability to directly affect lung function by modulating microbial composition 
through its antimicrobial activity, leading to alteration in the profile of circulating 
metabolites produced by commensal organisms [213-215]. It has been shown previously 
that phenolic compounds, such as harmol and phenol, undergo metabolism in the lungs 
[216, 217]. In addition,  pulmonary metabolism of RES was proven to occur following 
both intravenous and intra-arterial route of administration [218]. Therefore, we evaluated 
the effect of RES on the pulmonary microbiome in an OVA-stimulated mouse model of 
asthma.  
Akkermansia muciniphila is a gram-negative, non-spore forming, mucous-
degrading bacteria, previously identified as a beneficial gut microbe in many metabolic 
disorders, including obesity and Type 2 Diabetes. [219, 220]. Akkermansia muciniphila 
resides on the epithelial cell lining of the intestine, and affects epithelial gene expression 
via degradation of mucin and production of short chain fatty acids [221] . Specifically, 
Akkermansia muciniphila has been shown to increase the integrity of gut epithelium tight 
junctions and alter the expression of genes responsible for cellular metabolism [222, 
223]. 
In this work, we used an OVA-mediated mouse model of asthma to evaluate the 
effect of RES on lung function, gut and lung microbial composition, and  pulmonary 
epithelial cell gene expression. 
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3.4 Materials and methods 
3.4.1. Animals 
Female BALB/c mice aged 6-8 weeks were purchased from the Jackson 
Laboratories and housed in specific pathogen -free conditions. BALB/c mice   were then 
divided randomly into three groups (Naïve, OVA-VEH and OVA-RES) and kept in 
isolated cages. After one week of housing, at day 0 the mice were given 100 µl 
intraperitoneal injections containing 250µg chicken egg derived ovalbumin (OVA) 
dissolved in sterile phosphate buffered saline (PBS) solution containing 4mg/ml 
aluminum hydroxide. On days 1-14 the treatment group (OVA-RES) were administered a 
daily 200µl oral gavage of a solution containing 100 mg/kg resveratrol dissolved in 
carboxyl methyl cellulose (CMC). On days 1-14 the vehicle groups (OVA-VEH) were 
administered a daily 200µl oral gavage of carboxyl methyl cellulose (CMC).  Both 
groups of mice were then challenged with 50µg OVA suspended in 50 µl of sterile PBS, 
intranasally under light anesthesia at day 7. Mice were sacrificed by day 15 under 
anesthesia. 
3.4.2. Plethysmography for airway hyper reactivity assessment 
Airway functionality response to asthma induction was evaluated every 2 seconds 
following exposure to aerosolized PBS or acetyl methacholine (Sigma, St Louis, MO). 
Airway hyper-responsiveness was measured using 4-chamber, whole body 
plethysmography (Buxco, Troy, NY). Respiratory flow was measured by a 
pneumotachograph and transmitted to BuxcoFinePointe software for functional analysis 
in order to calculate respiratory rate (frequency), lung volume, lung tissue resistance to 
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flow, peak inspiratory and expiratory flow, and time intervals between breaths. Three 
mice were randomly selected from each experimental group and acclimated in Buxco 
chamber for 5 minutes. Baseline airway functionality levels were collected following the 
initial acclimation period for 5 minutes. Following baseline measurements, mice were 
then exposed to a brief two minutes exposure to aerosolized PBS followed by a two 
minutes exposure to 5 mg/ml of aerosolized methacholine for the purpose of inducing 
bronchoconstriction. Airway functionality parameters were measured for a period of 2 
seconds following methacholine exposure period. 
3.4.5. Profiling gut microbiota 
Gut contents were collected by conducting a cecal flush of excised whole colon 
contents using sterile PBS. Genomic bacterial DNA was collected from cecal contents 
using QIAamp DNA Stool Mini Kit (Qiagen, Valencia, CA) and quantified using a Qubit 
4 Fluorometer (ThermoFisher, Waltham, United States). Purified DNA was indexed with 
TrueSeqDNA PCR-free LT Library preparation kit for low-throughput studies (Illumina, 
San Diego, CA) according to the manufacturer’s instructions. DNA was PCR-amplified 
using primers for paired-end 16s community sequencing on the Illumina MiSeq platform 
using bacterial/archaeal primer sense 319 F/anti-sense 806 R targeting hypervariable 
regions V3-V4 of the 16S rRNA [38].   
3.4.6. Lung microbiome profiling 
Quick-DNA Fungal/Bacterial Midiprep Kits from Zymo Research (Zymo 
research Corp, Irvine, CA, USA) were used to isolate bacterial genomic DNA from 
lungs, under manufacturer’s instructions supplied within the kits. Briefly, 500 mg of lung 
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tissue was added to ZR Bashing/Bead lysis filtration tube with 6 ml of genomic lysis 
buffer containing β-mercaptoethanol (0.5% v/v). The tubes were placed in 50 ml –tube 
holder for 1 minute in high speed followed by centrifugation of ZR Bashhing/Bead Lysis 
Buffer tubes at 3,000 xg for 5 minutes. Following centrifugation, the samples were 
filtered through Zymo-Spin V-E Column Zymo Midi Filter Spin assembly that had been 
mounted in vacuum manifold with the vacuum pressure set to 600mmHg. After filtering 
the Zymo Spin VE, assembly was disconnected and transferred to collection tubes for 
centrifugation at 10,000xg for 1 minute. The flow through was discarded and 400 µl of 
genomic DNA-wash buffer was added to the column, centrifuged at 10,000 xg for 1 
minute and the flow through discarded. The Zymo Spin V-E Columns were then 
transferred to a 1.5 ml microcentrifuge tube and 150 µl DNA Elution Buffer was directly 
added to the column matrix and incubated at room temperature for 1 minute prior to 
centrifugation for DNA collection. DNA then was stored at -80 ͦC for profiling. DNA was 
quantified as sequenced as mentioned above. 
3.4.7. Immunofluorescent analysis of epithelial mucin 
Lungs were isolated from all experimental groups, fixed with 4% 
paraformaldehyde (SigmaMillipore) overnight, and embedded in paraffin. Five-micron 
sections were obtained and MUC5ac expression was detected by mouse monoclonal anti-
muc5ac (Abcam). The slides were then dewaxed and rehydrated with gradually 
decreasing ethanol gradient followed by PBS. Antigen retrieval solution (100 mM Tris, 
5% [w/v] urea, pH 9.5) placed in water bath heated for 95 ͦC. Slides were placed in a 
polypropylene Coplin Jar inside the preheated water bath for 10 minutes. They were 
removed and allowed to cool down slowly and a pap pen was used to circle the tissue. 
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Permealization buffer (0.1M% triton, 0.01M % Glycine in PBS) was added to the slides 
for 30 minutes followed by three washes with PBS each for 5 minutes. Blocking solution 
was 5% goat serum in 1% Bovine Serum Albumin (BSA) in PBS for 30 minutes 
followed by three washes with PBS, five minutes each. Then we added the primary 
antibody, anti-mouse mucin 5AC (ab3649) in 1 % BSA in PBS overnight at 4 ͦ C. The 
next day, the slides were washed with PBS and the labeling was performed using 
secondary antibody diluted 1:1000 in 1% BSA in PBS (Alexa Flour-488 conjugated goat 
anti-mouse antibody) (ab150113) for 2 hours in a 37 ͦ C incubator. Three washes with 
PBS were done, followed by counterstaining with DAPI (1:5000) (Thermo Fisher) 
(Cat#D1306) for 20 minutes on the shaker. Then slides were washed with PBS three 
times for 5 minutes each, mounted with Prolong Diamond Antifade Mountant (Thermo 
Fisher) (Cat#P36965) and visualized using Leica immunofluorescent microscope. 
3.4.8. RNA extraction from pulmonary epithelial cells and infiltrating pulmonary 
mononuclear cells 
Pulmonary epithelial cells were isolated as described previously [39]. Briefly, 
following sacrifice, the mice were subjected to a lung perfusion with cold sterile PBS 
followed by three lung lavages with cold sterile PBS using a 20-gauge catheter. A 
separate catheter was used to inject 1ml of dispase solution at a concentration of 25 U/ml 
into the lungs for a 30 second incubation period followed by 3 lavages with sterile, cold 
PBS. The lungs were harvested for physical disruption into various lobes in a well of 
sterile cold PBS. Each lung lobe was cut, then placed in 50 ml tube containing 25 U/ml of 
dispase and placed on a shaker for 45 minutes. After dispase digestions, the samples were 
combined with 10 ml of sorting buffer (DMEM in 2%FBS with 50 U/ml of DNase) and 
then incubated for 10 minutes at 37 ͦ C while shaking. The liquid suspensions following 
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the dispase digestions were poured through cell strainers containing pore sizes of 100µm, 
70µm and 40µM. The triple filtered suspension was then transferred to 15 ml tubes and 
centrifuged at 550xg for 5 minutes in 4 ͦ C. The collected pellet of cells was suspended in 
10 ml of sorting buffer and incubated for 1 hour at 37 ͦC while shaking. After incubation 
the cells were spun down at 550xg at 4 ͦC for 8 minutes and re-suspended in 700µl of 
Qiazol. RNA from lung epithelial cells was isolated using Qiagens RNeasy mini-kit 
(Qiagen, Germantown, MD).  
For isolation of pulmonary infiltrating cells, the mice were sacrificed and lungs 
were isolated and infused with cold, sterile PBS (Ca++and Mg++-Free). Lungs were then 
dissociated using a stomacher and RBC-lysis buffer was added at a concentration of 
250µg/ml for one minute. FACS buffer (2% FBS in PBS) was added to counteract the 
action of RBC-lysis buffer and samples were then centrifuged at 300 xg at 4 ºC for 10 
minutes. Following removal of the supernatant, the pellet was mixed with 5 ml of FACS 
buffer and then slowly added to 5mL of sterile Histopaque at room temperature in a new 
15 ml tube (Histopaque layering) [40]. The cells were then centrifuged for 30 minutes at 
500 xg at room temperature. The interphase representing the infiltrating mononuclear 
cells was then removed, added to another 15 ml tube and 10 ml of FACS buffer was 
added. Cells were centrifuged, the supernatant removed and Qiazol was added to the 
pellet. RNA was extracted using Qiagen`s RNeasy mini-kit (Qiagen, Germantown, MD).  
cDNA synthesized from total RNA content using Bio-Rads miScript kit using the 
manufacturer’s protocol (Bio-Rad laboratories, Hercules, CA). qRT-PCR was conducted 
on the generated cDNA library for detection of Cadherin-1, Claudin-18, ZO-1, Occludin, 
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PPAR-γ and PPAR-α mRNA and levels were normalized to GAPDH. qRT-PCR primer 
sequences used are available in Supplemental Table 1.  
3.5. Statistical Analysis 
Data are presented as mean ± SEM. Differences between more than 2 groups were 
assessed using one-way ANOVA test followed by Tukey post-hoc tests in Graph Prism 
V7.00 for Windows (San Diego, CA). Unpaired two-tailed Students t-test was used to 
compare between two experimental groups. Statistical significance (p value<0.05) in the 
figure was indicated by superscript (*). 
3.6. Results 
3.6.1. Plethysmography for airway hyper reactivity assessment 
At both baseline measurement and with methacholine challenge, a significant 
increase in the peak expiratory flow (PEF) as well as mean volume (MV) for OVA-RES 
group when compared to OVA-VEH (Fig. 1B, C, E and F). After challenging the mice 
with methacholine, the specific airway resistance (sRaw) was significantly increased in 
OVA-VEH group when compared to naïve, and RES-treatment significantly attenuated 
OVA-induced airway resistance (Fig. 1 C). In contrast to specific airway resistance, the 
specific airway conductance, sGaw, was reduced in mice challenged with OVA relative 
to naïve, unchallenged mice and this decrease in sGaw due to OVA challenge was 
inhibited by treatment with RES (Fig. 1F). The time delay between the thoracic and nasal 
flow (dT) lasted significantly longer in the OVA-VEH group when compared to naïve 
mice; furthermore, RES-treatment significantly reduced the time delay relative to OVA-
VEH mice (Fig. 1C). OVA-challenged mice that received RES  displayed more favorable 
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outcomes as evidenced by a significant increase in the frequency (F) and the mean 
volume (MV) of respiration, in comparison to OVA-challenged mice that received only 
VEH (Fig. 1C). The time of expiration and inspiration (Te&Ti) were both significantly 
reduced in RES-treated relative to VEH-treated OVA-challenged mice (Fig. 1F). 
3.6.2. Microbiota Profiles 
NEPHELE, an online platform for the analysis of microbiome data generated by 
the National Institute of Allergy and Infectious Diseases at the NIH, was used to classify 
reads into operational taxonomic units (OTUs) and further analyze the 16s sequences 
generated from cecal and lung contents collected. Several species were identified as 
being present in the cecal contents of mice in all groups (Fig. 2A); however, VEH-
treated, OVA-challenged mice displayed a significant reduction in OTUs corresponding 
to Bacteroides acidifaciens when compared to naïve mice (Fig. 2B). Interestingly, OVA-
challenged mice treated with RES had a significantly higher abundance of OTUs 
representing Bacteroides acidifaciens, suggesting restoration of B. acidifaciens levels 
upon RES-treatment (Fig. 2B). 
Analysis of lung microbial composition using NEPHELE identified the presence 
of several species in all three groups (Fig. 3A). The percentage of OTUs representing 
Akkermansia mucinuphilia was found to be greatly reduced in VEH-treated, OVA-
challenged mice when compared with naïve mice (Fig. 3B). Furthermore, there was a 
significant increase in the abundance of OTUs mapping to Akkermansia muciniphila in 
OVA-challenged mice treated with RES versus those treated with VEH, suggesting RES-
mediated protection of the Akkermansia muciniphila population upon induction of asthma 
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(Fig. 3B).  Predictive functional analysis of the microbial communities presents in the 
lungs of naïve, OVA-VEH and OVA-RES mice was performed using Phylogenetic 
Investigation of Communities by Reconstruction of Unobserved States (PICRUST), a 
bioinformatics software package present within the NEPHELE platform. We next used 
linear discriminant analysis effect size (LEfSe) to identify predicted functional 
biomarkers. OTUs mapping to the functional category of “Lipopolysaccharide 
biosynthesis proteins” were significantly enriched in OVA-challenged mice treated with 
VEH relative to those treated with RES, indicating a potential functional role for LPS 
synthesis by the microbial community present in OVA-challenged mice in driving asthma 
pathogenesis, that is absent in RES-treated mice (Fig. 3D).  Moreover, when analyzed for 
LPS, OVA-VEH mice had significantly higher levels of LPS in bronchial alveolar lavage 
fluid (BALF) compared to OVA-RES mice, in line with the LEfSe analysis (Fig. 3E).  
3.6.3. Immunofluorescent analysis of epithelial mucin 
Lung tissue slides were stained for MUC5ac protein. There was a significant 
increase in MUC5ac expression in OVA-challenged, VEH-treated mice as compared to 
naïve; however, RES-treatment significantly reduced MUC5a levels as measured by 
CTCF (corrected total cell fluorescence using image J from NIH) (p value < 0.05) 
(Figure.4) 
3.6.4. Tight junction molecule expression 
Real-time qRT-PCR revealed changes in the expression of genes that regulate 
tight junctions and epithelial barrier function. Pulmonary epithelial cells were taken from 
naïve, or VEH- and RES-treated, OVA-challenged mice and evaluated for the expression 
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of occluding, ZO-1, cadherin and claudin-18. Upon OVA challenge, there were 
significant decreases in the expression of all but one adhesion molecule evaluated, when 
compared to expression in epithelial cells from naïve mice; while cadherin expression 
was not significantly decreased upon OVA-challenge, it trended toward decreased 
expression (Fig. 5A). Furthermore, OVA-challenged mice receiving RES had 
significantly elevated levels of tight junction molecules in their pulmonary epithelial cells 
when compared to those receiving VEH, suggesting that RES may prevent or restore the 
decreased expression of these genes that occurs with OVA-challenge alone (Fig. 5A). 
3.6.5. PPAR-γ gene expression 
In addition to evaluating the adhesion molecules occludin, ZO-1, cadherin, and 
claudin-18, we evaluated the expression of PPAR-γ in both pulmonary epithelial and 
pulmonary infiltrating cells. RES-treatment resulted in increased gene expression of 
PPAR-γ in lung epithelial cells relative to both naïve and OVA-VEH (Fig. 5B). 
Additionally, while lung infiltrating mononuclear cells derived from OVA-VEH mice 
exhibited significantly lower levels of PPAR-γ relative to those-derived from naïve mice, 
lung-infiltrating mononuclear cells from OVA-challenged mice treated with RES had 
significantly higher levels of PPAR-γ relative to those from OVA-VEH mice, suggesting 
a role for RES in regulating barrier function in epithelial cells and gene expression in 
both epithelial and infiltrating cells (Fig 5C) during OVA-induced asthma.   
3.7. Discussion 
In this study, we demonstrate that the natural compound RES alleviates the 
immune response in an OVA-induced asthma model by possibly reshaping the gut-lung 
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microbiome. To show that resveratrol improves asthma, we assessed lung function using 
whole body plethysmography at both the basal levels as well as following challenge with 
methacholine, as previously described [224, 225]. The measurements of these parameters 
revealed that there was a deviancy from normality in lung function in the OVA-VEH 
group, characterized by a loss of general pulmonary function. According to the clinical 
parameters output, the OVA-RES group exhibited restored lung function and displayed 
lung functionality that was more characteristic of a naïve state. This trend was observed 
with statistically significant results for the dT, sRaw, PEF, F, Ti and Te. These collective 
results showed that in an OVA-induced mouse model of asthma, RES attenuates the 
pathology associated with asthma and reestablishes proper lung function. The lung tissue 
resistance, indicated by sRaw measurements, was significantly elevated in the OVA-VEH 
group compared to the OVA-RES group, which displayed restored sRaw measurements 
to those similar to the naïve group. A reduction in sRaw, in models of asthma, is often 
used to indicate disease mitigation in response to drug treatment [225-228]. 
Sequencing of the V3-V4 variable region of the 16s ribosomal RNA gene from 
the contents of the cecum revealed that the commensal microorganism Bacteroides 
acidifaciens was significantly lower in the OVA-VEH group when compared to naïve 
group and was significantly restored with RES-treatment. Previous studies have shown 
that a maternal diet rich in fibers indigestible to the host significantly increases the 
abundance of probiotic organisms, namely Bacteroides acidifaciens, which ferments 
these fibers resulting in SCFA production. SCFAs have been shown to induce the 
expression of transcription factor Foxp3 amongst T lymphocytes, directing their function 
towards that of tolerant, which in turn reduces fetal asthma incidence [229, 230].  
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The increased presence of this commensal bacterium amongst the RES treatment 
group suggests that the bacterial induction of immunotolerance may play a role in RES-
induced alleviation of OVA-induced allergic response [47, 181, 228-232]. 
Akkermansia muciniphilia is a gram negative, mucus-degrading bacterium that is 
considered beneficial when at appropriate levels and has been implicated in a variety of 
inflammatory disorders [231]. The increased colonization of Akkermansia muciniphilia 
within the gut epithelium mucosal layer has been shown to combat metabolic diseases. 
Additionally, it can improve gut microbiome dysbiosis by degradation of mucous, 
followed by subsequent production and release of SCFAs into the local environment, 
improving tight junction and recovered metabolism of adjacent epithelial cells [232, 233]. 
The observed increase in Akkermansia muciniphila within the lung microbiome of the 
OVA-RES group when compared to OVA-VEH suggests that RES may promote the 
outgrowth of this potentially beneficial organism, which in turn, enhances mucous 
degradation and clearing of excess mucus.  
Previous studies have shown that exposure to airway irritants reduces the 
expression of tight junction molecules occludin and claudin within the brochial 
epithelium, resulting in a lack of barrier integrity. Furthermore, the release of pro-
inflammatory molecules during an asthmatic incident has been known to cause disruption 
of tight junctions. The important relationship between the microbiome and epithelial cell 
tight junction molecules highlights the importance of our findings, indicating that RES 
treatment improves tight junctions, thereby interfering with exposure of sub-epithelial 
layer to microbial antigens. We assessed mRNA levels of tight junction molecules and 
found that major components of epithelial tight junctions (claudin, cadherin, occludin and 
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ZO-1) were significantly higher in the OVA-RES group when compared to the OVA-
VEH group (p value <0.05). This finding suggests that resveratrol may improve airway 
barrier integrity through the promotion of tight junction molecule expression, ultimately 
alleviating symptoms of asthma.  
Akkermansia muciniphila has been shown to ameliorate PPAR gene expression in 
intestinal epithelial cells and because this gene is related to development of immune 
tolerance [221, 223, 234]. We evaluated PPAR-γ mRNA expression by real time qPCR in 
both pulmonary epithelial cells and pulmonary infiltrating cells. Our work revealed that 
resveratrol significantly increased the expression of PPAR-γ gene in both pulmonary 
epithelial cells and infiltrating cells, following OVA-induced reduction.  
 In summary, the current study has shown that RES ameliorates the clinical 
parameters of asthmatic episodes and promotes a return to normalcy in the tissue 
architecture of the lung mucosa. In our model, the beneficial effects of resveratrol 
supplementation are accompanied by changes in both gut and lung microbial species. It is 
possible that the changes in species modulate the immune response in such a way that 
inhibits promotion or stimulates reversal of OVA-induced changes in airway function. In 
this study, RES promoted the growth of Akkermansia mucinuphila within the lungs and 
Bacteroides acidifaciens within the gut of OVA-challenged mice. As a mucous degrader, 
we believe that presence of Akkermansia muciniphila in the lung tissue was able to 
improve parameters of lung function through the alleviation of excessive mucous 
production, as well as by driving epithelial integrity. Within the gut Bacteroides 
acidifaciens outgrowth may help establish an immunotolerant environment through the 
production of SCFAs, which promotes the generation of T regulatory cells. This study 
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supports the use of RES, and perhaps other natural compounds, as potential novel 
therapeutics for the management of often incurable and costly inflammatory conditions, 
such as asthma. In addition, this study may help establish a better understanding of the 
extrinsic factors influencing the progression of autoimmune diseases. 
3.8. Ethics Statement 
All mice were housed at the American Association for the Accreditation of 
Laboratory Animal Care (AAALAC)-accredited Animal Resource Facility at the 
University of South Carolina, School of Medicine, Columbia, SC. All procedures were 
performed according to National Institutes of Health (NIH) guidelines under protocols 




Table 3.1. Primer sequences for qPCR analysis of lung epithelial cells` tight junction 
molecules and PPAR- γ gene. 
 
Primer Sequence 
Cadherin-1 (Forward) 5`-CAGGTCTCCTCATGGCTTTGC-3` 
Caherin-1 (Reverse) 5`-CTTCCGAAAAGAAGGCTGTCC-3` 
Claudin-18 (Forward) 5`- CCGCCGTGTTCCAGTATGAAG-3` 
Claudin-18 (Reverse) 5`-CGATCATCAGGGCTCGTACAG-3` 
Occludin (Forward) 5’-TTGAAAGTCCACCTCCTTACAGA-3’ 
Occludin (Reverse) 5`-CCGGATAAAAAGAGTACGCTGG-3` 
ZO-1 (Forward) 5`-GCCGCTAAGAGCACAGCAA-3 
ZO-1 (Reverse) 5`-TCCCCACTCTGAAAATGAGGA-3` 
PPAR-γ (Forward) 5`-TCGCTGATGCACTGCCTATG-3 
PPAR-γ (Reverse) 5`-GAGAGGTCCACAGAGCTGATT-3 
GAPDH (Forward) 5`-AGGTCGGTGTGAACGGATTTG-3` 




Figure.3.1: Resveratrol treatment restores lung function in asthma mouse model. 
Female BALB/c mice were initially sensitized by intraperitoneal ovalbumin+aluminium 
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hydroxide, followed by treatment for 7 days with carboxymethyl cellulose (ova-veh) or 
resveratrol in carboxymethyl cellulose. Intranasal ovalbumin challenge occurred on day 
7. On day 9, the mice were chosen randomly and placed in one of 4 chambers of Buxco 
instrument. A) Pulmonary function test shows F(frequency) , MV (mean volume), sRaw 
(specific airway resistance), dT (delay time). Bar graphs and statistical analysis for the B) 
baseline lung function C) and for lung function after challenge with 5 mg/mL 
methacholine. D) Pulmonary function test shows sGaw (specific airway conductance) , 
PIF (Peak inspiratory flow), Ti (Time of inspiration), Te (Time of expiration). Bar graphs 
and statistical analysis of E) baseline pulmonary function and F) after challenge with 5 
mg/ml methacholine. Data represent mean±SE from n=3, *P<0.05, **P<0.01, 





Figure 3.2: RES restores OVA-mediated decreases in gut B. acidifaciens. Colons 
were excised from experimental mice at day 14 and flushed with sterile PBS. Cecal flush 
stored at -80 and bacterial DNA was isolated. Miseq used for the analysis of gut 
microbiome. Heat map for the percentage of OTUs of bacterial species in the colon C) 
Bar graphs and statistical analysis of Bacteroides acidifaciens percent OTUs. Data 





Figure 3.3: Effect of RES-treatment on lung microbiome in OVA-challenged mice. 
A) Heat map for the lung microbiome bacterial species B) Bar graphs and statistical 
analysis of Akkermansia muciniphila percent OTUs. C) LEfSe analysis of predicted 
functional metagenomics (based on PICRUSt analysis) D) LPS levels present in the 
BALF of VEH- and RES-treated OVA-challenged mice. Data represent mean±SE from 

















Figure 3.4: Resveratrol reduces mucin in the lung tissues of OVA-challenged mice. 
A) Immunofluorescent analysis of lung tissue showing MUC5a expression and B) bar 
graphs and statistical analysis of immunofluorescence images using CTCF (corrected 
total cell fluorescence using image J from Data represent mean±SE,  *P<0.05, **P<0.01, 
***P<0.001 using one way ANOVA posthoc Tukeys test. 
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Figure 3.5: Resveratrol treatment alters the gene expression in the  pulmonary 
epithelial cells and pulmonary infiltrating cells.  qRT-PCR analysis of A) tight 
junction molecule expression in pulmonary epithelial cells or B) expression of PPAR-ɣ in 
pulmonary epithelial cells and C) pulmonary infiltrating cells. Significance (*P<0.05, 
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